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Abstract
Cell surface glycans, typically in the form of glycoproteins or glycolipids, are
commonly aberrant in diseases and can serve as biomarkers that facilitate diagnostics,
selective cellular labeling and delivery. Boronic acids have been extensively utilized for
the detection and separation of carbohydrates through reversible formation of boronate
esters in the binding of diol moieties on glycans. However, the biological application of
this sensing group is challenged by its relatively low binding affinity in aqueous media.
Through the research described in this dissertation, we designed and synthesized boronic
acid materials that can enhance its avidity towards glycan through multivalent binding
interactions to achieve biological applications including glycoprotein detection and
cellular delivery.
In the second chapter of this dissertation, a boronic acid microplate assay for
sensitive and high-throughput detection of the cancer-associated glycoprotein mucin-1
was developed. For this purpose, a multivalent surface for glycoprotein recruitment and
detection was achieved by immobilizing biotinylated boronic acid onto streptavidincoated microplates. In the third chapter, novel boronic acid lipids were synthesized and
incorporated into liposomes as a drug delivery platform. We validated carbohydrateresponsive liposome efficacy by demonstrating dose-dependent release of encapsulated
hydrophobic or hydrophilic fluorophores upon titration with the polysaccharide heparin.
Cellular delivery and labeling were visualized by confocal microscopy indicating a
iv

dramatic enhancement in fluorescence signal, showcasing the prospects of boronic acid
lipids for drug delivery. In the last chapter, bisboronic acid lipids containing a small library
of spacers of varying length between two boronic acid units have been synthesized to
study selective binding interactions towards sialic acids. Enhanced binding affinity
towards N-acetylneuraminic acid and the sialic acid-rich glycoprotein porcine mucin were
observed using bisboronic acid lipids, particularly when using a meta-xylene spacer. This
was detected via dye displacement competitive fluorescence assays as well as through
liposomal triggered release studies. Finally, dose-dependent fluorescence cellular
labelling was visualized using bisboronic acid liposomes. Collectively, these studies show
that the incorporation of boronic acids into complex architectures including microplate
surfaces and liposomes is effective for advancing applications such as the detection of
disease-associated carbohydrates in complex biological samples and the delivery of
therapeutic agents to cells.
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1. Introduction to boronic acids and drug delivery vesicles
1.1 Boronic acids: structure, property and application
1.1.1 Structure and property of boronic acids
Synthetically derived from boric acids, boronic acids are trivalent organic
compounds with one carbon-based substituent and two hydroxyl groups attached to
boron in a planar geometry.[1] Exempt from the octet rule, the sp2-hybridized boron atom
formally has only six valence electrons, and thus contains an empty p-orbital that renders
this group electrophilic. However, this is counteracted by donation of electrons from
attached oxygen atoms, resulting in a low energy p-orbital. To be able to exist stably and
fulfill the octet rule, boronic acids and their esters may coordinate with basic molecules.
To do so, they commonly act as mild organic Lewis acids that accept lone pairs of
electrons.
As illustrated in Figure 1.1, there are three families of boron-based acids: boric
acid, boronic acids and borinic acids, and all can form either neutral or anionic esters,
depending on pH, upon reaction with diols through loss of water. Boric acid can form
neutral borate esters or anionic borate mono/diesters, while boronic acids can form
neutral or anionic boronate monoesters and borinic acids can only form anionic borinate
esters upon reaction with diols or divalent ligands.
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1.1.2 Complex equilibrium of boronate anion in aqueous environment
The acidic character of the boronic acid group has been an interest among
chemists for over a century. Lorand and Edwards reported the first mechanism of polyol
complexes of boronic acid and elucidated the structure of the conjugate base of boronic
acid (boronate ion).[2] As illustrated in Figure 1.2, in aqueous solution, boronic acids in
trivalent neutral form are in equilibrium with the anionic tetrahedral form (Figure 1.2B).
This demonstrates the Lewis acidity of boronic acid because the anionic tetrahedral form
of boronate was observed rather than the structure corresponding to a Brønsted base
that would result from the reaction shown in Figure 1.2A.
The acidity of the boronic acid moiety is characterized by its ability to ionize water
and produce hydronium ions, as illustrated in Figure 1.2B. Boronic acids with lower pKa
values are equipped with more electrophilic boron atoms that attract nucleophiles,
resulting in the formation of anionic tetrahedral hydroxyboronate anions. The pKa values
of boronic acids in aqueous solution are measured by UV spectrophotometry and 11B NMR
spectroscopy. Listed in Table 1.1, pKa values of boronic acids have been reported by
various research groups.[3-11] In general, arylboronic acids have lower pKa values than
alkylboronic acids. Bulky substituents proximal to the boron atom contribute to higher
pKa values because of the steric hindrance present upon formation of the tetrahedral
boronate ion. For example, 2-methoxyphenylboronic acid (pKa = 9.0) is less acidic than 3methoxyphenylboronic acid (pKa = 8.0).[4, 5] The presence of electron-withdrawing
groups on the phenyl ring of arylboronic acids has significant impact on acid strength. For
2

example, the presence of electron withdrawing ester and nitro substituent drops the pKa
of 3-methoxycarbonyl-5-nitrophenyl to 6.9.[11]
Reported by Wulff and coworkers, the pKa values of boronic acids can be lowered
by neighboring group participation of ortho-dialkylaminomethyl substituent.[12] Several
mechanisms are proposed to explain the role of anchimeric assistance in acidity of
boronic acids.[13-16] It has long been believed that Wulff-type boronic acids undergo
intramolecular chelation of amine groups to form B–N bonds. As a result, the
hybridization of the boron atom remains tetragonal boronate anion (sp3) under neutral
or slightly acidic conditions, which favors its interaction with diol-containing compounds.
However, recently, the Anslyn lab leveraged results from 11B NMR, fluorescence titration
and X-ray crystallography experiments to argue that the decrease in pKa of Wulff-type
boronic acids is due to the addition of an electronegative substituent in the aryl ring, such
as the protonated ammonium group in this case.[17]

1.1.3 Boronic acid-diol equilibrium in water and protic solvent
The boron–diol interaction plays a critical role in human health, plant growth, and
in bacterial quorum sensing.[18, 19] Boron-based compounds can serve as affinity ligands
for purification of glycoproteins, nucleotides and carbohydrate transporters, and are also
employed as protecting groups for carbohydrates.[20, 21] The first reported boron–diol
interaction was discovered by Biot in 1832.[22] His paper reported that the optical
rotation of tartaric acid changes following treatment with boric acid. A century later the
3

interaction between boronic acids and diols were intensely studied. In 1913, Böeseken
first reported that the acidity of boric acid increased in the presence of glucose.[23] In
1954, Schultz and coworkers reported the structure of aqueous borate ion by examining
its Raman spectrum.[24] In 1959, as shown in Figure 1.3, Edwards and co-workers
reported quantitative affinities of boric and phenylboronic acids with simple diols and
monosaccharides in aqueous solution.[2] The complex equilibrium between model diols
and monosaccharides was measured by applying a series of pH depressions. It was
concluded that the binding equilibrium is pushed towards the formation of boronate ions
when the solution is more basic.
In 2002, Wang and coworkers reported a detailed examination of boronic aciddiol complexation.[25] They found that the pKa of phenylboronic acid dropped from 8.8
to 6.8 and 4.5 when it formed neutral cyclic borate esters with glucose and fructose,
respectively, which indicated that the neutral boronate ester is more acidic than the
original boronic acid. Therefore, the boronic acid is less likely to interact with diols when
the pH of the solution is relatively low due to the enhanced acidity of the resulting
boronate esters. When the pH is elevated, the hybridization of boron shifts from sp2 to
sp3, which results in a significant release of angle strain that aids in driving the formation
of anionic hydroboronate complexes. To support this theory, Pizer and coworkers
reported that stability constants of complexes increase when the aryl substituent on
boronic acid is an electron withdrawing group.[3] It is also suggested that the equilibrium
constants (Keq) fall into the range of 103- 104 for tetracoordinate hydroxyboronate anion
4

when forming ester with diols and it is at least 104 times faster than trigonal neutral
boronic acid.[26]
Besides solution pH, the geometry of the hydroxyl groups located in the polyol
binding moieties also plays an important role in boronic acid binding interactions.
Measured by pH titration and 11B NMR spectroscopy, equilibrium constants of 2.5, 5.5
and 38 were reported for the binding interactions of 1,3-propanediol, 1,2-ethanediol and
1,2,3-propanetriol, respectively, with methylboronic acid.[28] 1,2,3-Propanetrol was
much preferred due to the proper cis-diol geometry

present in its preferred

conformations. The relative affinity of boronates for diols that exist in most carbohydrates
is in the order of cis 1,2-diol > cis 1,3-diol >> trans 1,2-diol. Therefore, certain
monosaccharides with favored diol geometries have intrinsically higher affinity than
others. The association constants of phenyl boronic acid and common diol-containing
compounds at pH 7.4 in 10mM phosphate buffer were reported by Wang’s lab and are
summarized in Table 1.2.

1.1.4 Boronic acid-based receptors and sensors for carbohydrates
The chemistry of the boronic acid diol interaction has enabled a broad spectrum
of applications. A variety of boronic acid materials can be used as supports for the
capture, recognition, and analysis of diol-containing compounds including saccharides,
glycoprotein and glycolipids. Examples of such boronic acid materials include
microporous monoliths, mesoporous materials, nanoparticles, molecularly imprinted
5

polymers, polystyryl boronic acid resins, and temperature-responsive materials.[29-36]
One of the most important applications of boronic acid materials is in the enrichment and
quantification of glycopeptides and glycoproteins.[37-39]
The Boons lab reported a new strategy for solid-supported oligosaccharide
synthesis by using polymeric supported polystyrylboronic acid 1.1 (Figure 1.4), where
saccharide intermediates can be released and loaded by heat and treatment with solvent
mixture.[40, 41]The Lin lab developed a high-throughput method for fabricating a stable
and covalent carbohydrate microarray.[42] This approach enabled the study of
carbohydrate-protein interactions by immobilizing carbohydrates through boronate ester
formation using boronic acids of type 1.2 (Figure 1.4) fixed on the glass surface and
hydroxyl groups of carbohydrates. In 2012, Zhang and co-workers developed a
biorthogonal method for modifying magnetic nanoparticles with boronic acid 1.3 (Figure
1.4) using azide and alkyne click chemistry.[43] In 2013, the Liu lab reported magnetic
nanoparticles with dendrimer-assisted

1.4 (Figure 1.4),

which showed significant

enhancement in boronate avidity for the selective enrichment of trace glycoproteins due
to the formation of multivalent binding interactions.[44] Besides carbohydrates, boronic
acid materials can act as a tool for the identification and purification of other diolcontaining compounds, including nucleic acid derivatives containing vicinal cis-diols as
well as small chemicals with catechol groups including L-DOPA, catechol estrogens and
catecholamines.[45, 46]

6

1.1.5 Biological and medicinal applications of boronic acids
After the first fluorescent boronic acid-based carbohydrate sensor 1.5 (Figure 1.4)
reported by Yoon and Czarnik in 1992, the ability of boronic acids to form esters reversibly
with cis-diols has aroused great interest in the intensive area of sensor and receptor
development for monosaccharaides, sugar acids, oligosaccharides.[47, 48] For
monosaccharides, various boronic acid-based sensors have been developed as blood
glucose monitoring devices for diabetes patients.[49] For sugar acids, boron-based
sensors have shown great affinity towards tartaric acid, glucuronic acid, and galacturonic
acid, as well as sialic acid.[50-54] Focus has since shifted to the development of receptors
for complex cell-surface glycoconjugates. The detection of Lewis X, heparin, and
Thomsen–Friedenreich (TF) tumor marker by boronic acid-based sensors has been
achieved by various research groups.[55-60] In 2002, Wang’s lab developed a fluorescent
bis-boronate sensor 1.6 (Figure 1.4) targeting the specific cancer-related oligosaccharide
epitope, sialyl Lewis X.[61, 62] The groups of Kataoka and Miyahara have also developed
novel methods for quantitative detection of cell-surface sialic acids by immobilized
boronic acid-based sensors 1.7 (Figure 1.4) on gold electrode platforms.[63-65]
An essential aspect to achieve stronger binding interaction with diols when
designing boronate affinity material is to lower the intrinsic pKa. For most biological
applications, recognition and detection occurs at pH values around 7.4. Therefore, to
obtain higher affinity towards diol-containing compounds, the pKa of the boronate affinity
material should stay close to or even lower than 7.4. Phenylboronic acid (PBA) is one of
7

the most used boronic acid ligands for developing boronate affinity materials. However,
due to its relatively high pKa values, a basic surrounding pH is usually required for binding
interaction. [27]
So far, as summarized by Liu and coworkers, four types of modified boronic acids
with intrinsic low pKa values have been developed.[66] As shown in Table 1.3, (I) for
boronic acid ligands with electron-withdrawing groups such as nitro, fluoro, sulfonyl and
carbonyl, the presence of the EWG on the aryl ring can increase the acidity and lower pKa
values.[35, 67-70] (II) In Wulff-type boronic acids that may contain intramolecular
tetracoordinated B–N or B–O bonds, the hybridization of boron atoms remains sp3
(tetrahedral) for boronate anions under neutral or slightly acidic conditions, which favors
its interaction with diol-containing compounds.[12, 71, 72] (III) Benzoboroxoles are
viewed as improved Wulff-type boronic acids due to the fact that intramolecular
tricoordinated B–O bonds have the same effect as intramolecular tetracoordinated B–N
or B–O bonds.[59, 73, 74] Another advantage of benzoboroxole is its excellent
hydrophilicity that can be beneficial for biological studies. (IV) Heterocyclic boronic acids
with the presence of a heteroatom (N, O, or S) in the ring, which lower the binding pH.[75,
76]
In this dissertation work, we aimed to develop novel boronic acid materials that
can recognize carbohydrates, glycoproteins and cell surface glycans, and ultimately serve
as agents for cellular drug delivery. To do so, boronic acid moieties were installed on lipid
scaffolds to form boronic acid lipids that can be incorporated into liposomes as drug
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delivery vesicles. Background information on lipids, liposomes and drug delivery vesicles
is discussed in the section below.

1.2 Introduction to drug delivery vesicles
1.2.1 Structure, property and biological roles of lipids
Lipids are biomolecules that are highly soluble in nonpolar organic solvents such
as chloroform. Simple lipids such as triacylglycerols or triglycerides are triesters consisting
of one glycerol linked to three fatty acids. These simple lipids act as energy storage units
among animals. The major reservoir of triacylglycerols resides in the cytoplasm of
mammalian adipose cells. The amount of total energy stored in a standard 70 kg man is
distributed in 0.17 MJ in glucose, 2.5 MJ in glycogen, 105 MJ in protein and 420 MJ in
triacylglycerols.[78] Besides energy reserves, lipids can exist in more complex structures,
such as phospholipids, glycolipids, and cholesterol, and act as major building blocks of cell
membrane bilayers.[79] Lipid membranes are planar, two-dimensional fluids that
separate either cells from the surrounding environment or the cytoplasm of cells from
organelles.
Complex lipids can be divided into four main groups: the phospholipids, sterols,
sphingolipids and glycolipids, as shown in Figure 1.5.[81] Among all, the most important
and abundant lipids is the class of phospholipids. Most phospholipids are glycerol-based
derivatives and are also named phosphoglycerides. Sterols, such as cholesterols and
derivatives, occur naturally in plants, animals, and fungi, and are important components
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of biomembranes.[82] They can also function as precursors to various vitamins and
hormones. Sphingolipids comprise a complicated class of lipids with a common sphingoid
base backbone as a synthetic product of the natural amino acid serine and a long fatty
acyl chain CoA.[83] Major sphingolipids include ceramides, which contain an amide-linked
fatty acid, phosphosphingolipids, and glycosphingolipids.[84] Glycolipids are lipids with
fatty acids attached to a monosaccharide or oligosaccharide via glycosidic linkage. They
play an important role in cell membrane stability and serve as recognition sites for cellular
interactions.[85] [86]
In this section, the main focus is on the structures and properties of
phosphoglycerides that were utilized during the course of this dissertation work. The
general structure of phosphoglycerides is shown in Figure 1.6.[80] The phosphoglycerides
are built up based on one glycerol backbone with two fatty acids that are 12-20 carbon
atoms in length esterified to the sn-1 and sn-2 position of glycerol. The sn-3 position of
glycerol is where the headgroup is attached, which is in the form of a phosphodiester
group in phospholipids. Different classes of phospholipids contain different groups
attached onto the phosphodiester moiety of the headgroup. With the hydrophobic fatty
acids and hydrophilic phosphate headgroup, phosphoglycerides are amphiphilic. Due to
the variation in the specific alcoholic group and fatty acids with different degrees of
saturation degree and chain length, a large variety of phosphoglycerides exist in nature.
The nomenclature of phosphoglycerides is based on the alcoholic head groups as listed in
Table 1.4.
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1.2.2 Types of delivery vesicles
The concept of drug targeting was first introduced by Paul Ehrlich in the early
twentieth century.[87] Ehrlich claimed that in order to increase the accumulation of an
active pharmaceutical ingredient (API) in a targeted area of the body, two components
were needed – the first one functioned for binding and recognition of the target while the
other one functioned as a therapeutic agent for the target.[88] Now, almost a century
later, with diligent efforts put forth by scientists around the world, as illustrated in Figure
1.7, several pharmaceutical carriers have proven to be efficient for binding and
recognition of the targeted cells, tissues and organs in human and animals, including
synthetic soluble polymers, microcapsules, microparticles, cells, cell ghosts, liposomes,
and micelles.[86, 89, 90] These drug delivery vehicles can minimize drug degradation after
intake, prevent undesired side-effects, and increase the bioavailability as well as
enrichment of drugs in the pathological area. Besides, they are relatively easy and cheap
to make, biodegradable with small particle size, of high loading capacity and exhibit
prolonged circulation.[91] Each class of delivery vesicles has its pros and cons, and thus
the selection of the most efficient vesicle varies depending on the application.
For synthetic soluble polymers, these can be ideal drug carriers for their desired
profile of drug pharmacokinetics, enrichment in the targeted site and drug release. The
most widely used polymer materials include N-(2-hydroxypropyl)-methacrylamide
(HPMA) copolymer and poly(ethylene glycol) (PEG).[92] However, their highly-complex
structures and high molecular weights may pose threats to mammalian cells.[93]
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Microcapsules and microparticles refer to particles with a size of 1 to 100 μm.
These have been established as unique carrier systems for many drugs and tailored to
adhere to certain pathological tissue systems.[94] One representative example of
microparticle drug delivery systems is to utilize surface modified microparticles with
protein shell.[95] Microparticles can enter targeted areas through cross-linking with a
second protein or an antibody to its protein shell.[96]
An additional promising delivery system that also happens to be the topic of this
dissertation is liposomes. Liposomes are artificial phospholipid bilayer vesicles that can
be prepared in various methods to different sizes, components, structures and size
distribution. The sizes of liposomes depends on their lipid composition and preparation
method and can range from 50nm to greater than 1000nm in diameter.[97] MLVs
(multilamellar vesicles) are liposomes with a size of 500 to 5000nm and consist of multiple
concentric bilayers. LUVs (large unilamellar vesicles) range from 200 to 800 nm and SUVs
(small unilamellar vesicles) are no more than 100nm in diameter. All unilamellar vesicles
are formed by a single membrane bilayer.
Micelles represent colloidal dispersions with particle sizes ranging from 5 to 50–
100 nm.[98] They can be self-assembled by amphiphilic molecules (lipids) or surfaceactive agents (surfactants), which consist of two opposite affinities toward either polar or
non-polar solvent. Due to their inherent and modifiable properties, micelles are wellsuited vesicles for drug delivery purpose.
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Liposomes have been considered promising drug delivery vesicles for over two
decadessince they are biocompatible, low-cost, easy to modify and of quick
administration. A liposome injection method has already been on the market for some
drug formulations, such as DaunoXome (danorubicin) and Myocet (doxorubicin).[99, 100]
Since the liposome is a major topic in this dissertation, more detailed discussions of
liposome composition, preparation methods, characterization, classification and
liposomal drug delivery can be found in the following sections.

1.2.3 Composition of liposomes
Due to the amphiphilic nature of lipids, they can form a variety of self-assembled
structures, such as spherical micelles, cylindrical micelles, spherical bilayers, or planar
bilayers.[101] Micelles are single-layered lipid aggregates that have hydrophilic heads
facing outwards and hydrophobic tails facing inwards. On the other hand, Bilayers are
two-layered sheet with hydrophilic heads pointing both outside and inside, and with
hydrophobic tails pointing toward the center of the sheet. Introduced by Israelachvili in
1976, the packing parameter ρ is used to describe the structural shape of different classes
of hydrocarbon amphiphiles that can be used to understand the formation of micelles or
#

bilayers.[102] The equation used to calculate ρ is ρ = $% where & is the volume, ' is the
cross sectional area of the headgroup, and ( is the length of the tail.
As illustrated in Table 1.5, when the packing parameter of a certain class of lipids
is less than one third, a spherical micelle is formed. An example of a micelle-forming lipid
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is lyso-phosphatidylcholine (LPC) with only one acyl chain on the glycerol backbone. As
the tail shortens and ρ is between one third to one half, reversed micelles are formed
with the hydrophilic heads facing outwards and hydrophobic tails facing inwards, which
then assemble into inverted hexagonal shape.[103] A representative lipid with ρ between
one third to one half is PE. When the tail continues to be shortened to the point that p is
between one half and one, a spherical bilayer is formed. Lipids with higher ρ contribute
more to the stability of bilayer membranes while more flexible bilayers are most likely be
generated by lipids of ρ closer to one half. Phosphatidylcholine has a ρ value close to one
and is used as a major component of liposomes due to its ability to form stable planar
bilayers.
To form the desired assembly, the choice of lipids is crucial. As mentioned before,
PC can self-assemble into spherical bilayer liposomes due to its cylindrical structure. As a
result, most liposomes are composed of natural and/or synthetic phospholipids, including
phosphatidylcholine as a major component, as well as PE, PS, and PG. Because
phospholipids have an intrinsic flip-flop tendency that facilitates leakiness of liposomes,
cholesterol can be added to the formulation of liposomes to increase the stability of
bilayers.[97, 104-106] Kirby and coworker reported that cholesterol-rich (egg
phosphatidylcholine/cholesterol, 7:7 molar ratio) liposomes, when intravenously
injected, remained stable in the blood for up to at least 400 minutes regardless of surface
charge.[107] Another study has suggested the level of cholesterol can increase the vesicle
size.[108]
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Besides packing parameter, other properties of lipids are also important to the
formation of desired assembly. One example would be the phase transition temperatures
(TM) of phospholipids. Lipid bilayer membranes can exist in either a disordered fluid
crystalline state (T > TM), where the hydrocarbon chains are randomly oriented and fluid,
or an ordered gel phase (T < TM), where the hydrocarbon chains are fully extended and
closely packed, depending on the temperature. Several factors directly affect the phase
transition temperature including hydrocarbon length, unsaturation, charge, and
headgroup species. Typical phospholipids and their transition temperatures are listed in
Table 1.6. For drug delivery purposes, phospholipids with proper TM values remain in the
gel state when forming liposomes and encapsulating drugs and change into the fluid state
at body temperature. When lipids are in the fluid state, they are more permeable to
aqueous solution and drugs can be encapsulated during liposome formation.[109] At
body temperatures (T ≈ 37 °C), a fluid state will make the liposomes leaky, and the
encapsulated drugs are likely to be released, ideally at the targeted area.
Charges of component lipids can also greatly affect the property of
liposomes.[110] Like lipids, liposomes can have either negative, neutral or positive
charges, and liposomes of the same charge are less likely to aggregate due to electrostatic
repulsion. Positively charged liposomes such as those containing N-[1(2,3dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTAP) are commonly used for
drug delivery due to several benefits.[111] First, they can increase cell-liposome
recognition, interaction and ultimately cellular entry by electrostatic attraction to cell
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membranes, which typically are of negative charge.[112] Besides, cationic liposomes are
more useful for encapsulating negatively charged compounds such as nucleic acids.

1.2.4 Methods of liposome preparation
The size, lamellarity, and encapsulation efficiency of liposomes can be varied
depending on the methods of preparation. Generally speaking, liposomal preparation
methods can be categorized as conventional methods and novel methods. The first
method for preparing liposomes was reported by Bangham and co-workers in 1976.[113]
This method, named after its inventor as the Bangham method or later known as thin lipid
film hydration method, involves creating a thin lipid film on a glass surface by evaporating
the organic solvents used to dissolve lipids and then a freeze-thaw procedure to
guarantee the complete removal of organic solvents. Liposome formation happens after
rehydration with aqueous solutions.
Multilamellar vesicles (MLVs) with heterogeneous size distribution are formed
with vigorous shaking during rehydration.[114] To obtain vesicles of smaller or more
uniform sizes, additional reduction techniques are necessary. For example, small
unilamellar vesicles (SUVs) with homogeneous size can be generated with probe
sonication. With a titanium probe inserted into the lipid rehydration process, SUVs of
desired size can be generated effectively.[115] However, SUVs may be contaminated due
to physical contact with metal sonicator probes and phospholipids can be damaged by
high temperature exposure. To avoid these risks, most liposomes in this dissertation work
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are prepared by using multiple extrusions through a polycarbonate membrane to reduce
the sizing.[116] The size of liposomes relies on the number of extrusion cycles and the
size of polycarbonate membrane pores. Although not an issue in this dissertation work,
low aqueous core entrapment and subsequently low drug encapsulation is a major
drawback of this technique.[117]
The conventional techniques for liposome preparation are straightforward for
small-scale laboratory setting but are not suitable for large-scale industrial production
due to random encapsulation efficiency, batch-to-batch variation, broad size distribution
and difficulty in sterilization. With more recent advances in physics and material science,
novel methods including micro hydrodynamic focusing (MHF), single hydrodynamic
focusing (SHF), double hydrodynamic focusing (DHF), supercritical reverse phase
evaporation (SRPE), and supercritical antisolvent (SAS) have been applied to large-scale
liposome preparation.[118-121]

1.2.5 Characterization of liposomes
With the development of liposome drug delivery system, several liposomal
formulations, such as doxorubicin, daunorubicin, and amphotericin containing liposomes,
have successfully reached the market place. To ensure proper liposome performance,
batch to batch reproducibility, and stability of the liposome dispersions, Crommelin and
Storm have listed several ways to characterize the liposomes, which are discussed in the
following section.[122] .
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Perhaps the first thing to discuss about liposomes is their size and polydispersity
since liposome size is critical for parenteral drug administration, batch to batch quality
and variations in manufacture. Methods of liposomal size measurement include dynamic
light scattering (DLS), size exclusion chromatography (SEC), nuclear magnetic resonance
(NMR), transmission electron microscopy (TEM), cryogenic-TEM (Cryo-TEM), and atomic
force microscopy (AFM). The easiest, also most used in this dissertation, technique to
measure the liposome size and size distribution is DLS. DLS analyzes the Brownian motion
of small particles suspended in aqueous solution resulting in scattering of the incident
light. The amount of light scattered is collected and analyzed to give an average size and
size distribution of the colliding liposomes. DLS has a wide range of measurement
capability (20 – 1000nm) but this technique is sensitive to impurities and cannot
differentiate between an individual liposome from liposomal aggregation.[123, 124]
The size of the liposome is an important factor for extravasation and circulation in
drug delivery. Liposomes with large diameters (> 400nm) cannot circulate in the blood
stream for long since RES uptake can occur in a short period of time after
administration.[125, 126] On the other hand, liposomes with short diameters (~ 200nm)
can remain in circulation for a long time. The extravasation of liposomes from blood
vessels to pathological area is an outcome caused by local blood flow and microvascular
permeability.[127] One of the concepts that comes with this is the enhanced permeability
and retention (EPR) effect.[128, 129] In order to provide enough nutrition for malignantly
spitting cancerous cells, abnormal vessels are found in tumor tissues, in terms of
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abundancy, leakiness, metastasis and so on.[130] Liposomes of appropriate size can
accumulate relatively easily into tumors tissues through vascular fenestrations and can
be retained for a prolonged period time due to the lack of lymphatic drainage.[131] This
makes liposomes and other nanoparticles particularly effective for targeting cancerous
tissue.
The second aspect related to characterization of liposomes is zeta potential.
Liposomes can be negatively or positively charged or uncharged depending on lipid
composition and associated ligands. Zeta potential measures the overall charges of
liposomes in dispersion and can serve as an index for the stability of the liposomes.
Uncharged or low charged liposomes are generally more likely to aggregate over time. In
comparison, highly charged liposomes, negatively or positively, are electrostatically
repulsive to each other and are less likely to cluster. Zeta potential can be measured by
fluctuations in the scattered light using DLS.
Encapsulation efficiency (EE) is another important property of liposome for drug
delivery purpose. To obtain a precise measurement of EE, unencapsulated free drug must
be removed from suspension by ultracentrifugation, dialysis, or size exclusion
chromatography. Next, to release encapsulated drugs, organic solvents, such as
acetonitrile, ethanol, and methanol, or surfactants including Triton X-100 can be added
to disrupt the integrity of liposome structure. Several techniques can be applied to
estimate the abundance of encapsulated content including UV and/or fluorescence
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spectroscopy, enzyme- or protein-based assays, gel electrophoresis, HPLC, UPLC, and
LC−MS.[132]
Last but not the least, the number of bilayers, in other words lamellarity, is an
important parameter in regard to liposomal in vivo lifespan and applications. To estimate
the number of layers, chemical-based techniques often utilize labeled reagents or
radiolabeled ions because these reagents can be uniformly distributed on the surface of
outer layer, either to the polar or apolar region of lipid molecules.[133, 134] Other
techniques, such as cryo-TEM analysis, 31P NMR, small-angle X-ray scattering (SAXS) can
also measure liposomal lamellarity.[135-137]

1.2.6 Different types of liposomes
As illustrated in Figure 1.8, there are four main types of liposomal drug delivery
systems:

conventional

liposomes,

stealth-stabilized

liposomes,

ligand-targeted

liposomes, and a combination of the above.[138] Because of their ability to reduce
toxicity compared to free drugs, conventional liposomes are the first generation of
liposomes for drug delivery purposes and their clinical application for drug encapsulation,
such as doxorubicin and amphotericin, has been studied since the early 1980s.[139-142]
Conventional liposomes can be positively or negatively charged or uncharged depending
on the presence of either cationic, anionic or neutral phospholipids and cholesterol. The
main drawback of conventional liposomes is the short lifetime in vivo and quick
elimination by the reticuloendothelial system (RES) in mammalian systems.[143]
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One aspect that hindered the application of liposomal drug delivery systems in the
early days involved the short circulation lifetimes of liposomes. To improve liposome
stability and increase their circulation times in the bloodstream, long-circulating liposome
(or stealth-stabilized liposomes) that have polyethylene glycol (PEG) chains conjugated
on the liposomes surface were introduced that shield liposomes from degradation and
therefore enhance accumulation at the targeted pathological area.[144, 145]. The
installment of this steric barrier shields liposomal encapsulated agents from opsonization
with serum components, and rapid recognition and uptake by RES.[146]
For site-specific delivery of drugs to certain pathological cells, organs or tissues,
ligand-targeted liposomal systems have proven to be effective for they can selectively
recognize specific ligands that are often over-expressed at the site of the disease.[147] A
variety of ligands can serve as targets, such as antibodies, peptides, proteins,
carbohydrates, and other small molecules.[148, 149] Since liposomes are self-assembled
and dynamic, with proper position of ligands affixed on the liposomal surface, optimal
substrate-interaction can be achieved by ligand-targeted liposomes.
In recent years, a newer generation of liposomes

termed theranostic liposomes,

has been developed. They combine the merits of the three aforementioned drug delivery
platforms in this section and, as a result, can further improve liposomal stability, specific
targeting and delivery.[150] Zhan and coworkers reported synthetic DCDX-modified
stealth liposomes with CDX retro-inverso peptide located on the liposomal surface that
can specifically bind to CDX ligand, along with steric stabilization using PEG.[151] This type
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of long-circulating immunoliposomes proved to be immunocompatible and significantly
enhance drug delivery efficacy.

1.2.7 Liposomal drug delivery
As illustrated in Figure 1.9, liposomal drug delivery can generally be categorized
into active targeting and triggered-based targeting. Active targeting can be achieved by
liposomal surface decoration with target-specific ligands and/or antibodies. On the other
hand, triggered-based targeting utilizes internal stimuli, such as pH or enzymes, and
external stimuli, such as ultrasound, heat, light, magnetic field.[109]
For active targeting strategies, antibody surface-modified liposomes have been
intensively studied for their ability to selectivity target diseased cell or organs through the
antigen-antibody interaction of specific antibody fragments and monoclonal antibodies
affixed on liposomal surface.[152] Munster and coworkers have designed PEGylated
doxorubicin liposomes with antibody fragment MM-302 coupled to the outer surface for
breast cancer treatment.[153] MM-302 can specifically bind to HER2-overexpressed
tumor cells with minimal uptake into healthy cells which express low levels of HER2. This
antibody surface-modified liposomal drug delivery system has been under clinical trial to
test its toxicity, patient response and clinical benefit.
Since tumor cells have highly variable physiological properties, such as relatively
low pH compared to normal cells and over-expression of certain enzymes or glycans,
those variations can serve as internal stimuli for liposomal triggered release.[154, 155]
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Yao and coworkers have reported a pH-dependent fusion method between liposomes
and cellular membranes using pHLIP® (pH Low Insertion Peptide).[156] pHLIP
preferentially anchors into lipid bilayers at low pH. The pHLIP-modified PEGylated
liposomes can enhance membrane fusion, which leads to an increase of cellular uptake,
content release and inhibition of cellular proliferation.
For external stimuli-mediated drug delivery, heat, ultrasound, magnetic field, and
light are common stimuli for liposomal triggered release. Lysolipids play a major role in
thermosensitive liposome for they are structurally different from generally used
phospholipids and tend to form micelles on their own.[157, 158] Lipid bilayers of lysolipid
thermosensitive liposomes (LTSL) transfer into an unstable gel state when heated and
lysolipids can assemble into micelle-like structures and maximize drug release. Tak and
coworkers reported lyso-thermosensitive liposomal doxorubicin (LTLD) that can locally
release a high concentration of doxorubicin and improve the efficacy of radiofrequency
ablation (RFA) for hepatocellular carcinoma (HCC) lesions.[159] Echogenic liposomes
serve as great tools for diagnostic imaging and ultrasound mediated drug/DNA delivery.
The McDannold lab developed liposomal microbubbles that can permeabilize blood-brain
barrier (BBB) when applied to focused ultrasound (FUS).[160] This technique has been
investigated in an animal study and can be a noninvasive method for targeted drug
delivery in the brain. Magnetically sensitive liposomes (MLs) consist of stabilized iron
oxide particles and can be controlled for targeting and drug release by external magnetic
field. Nobuto and coworkers reported magnetic doxorubicin liposomes that significantly
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suppressed primary tumor growth and enhanced the antitumor effect of systemic
chemotherapy compared to standard methods in hamsters inoculated with
osteosarcoma.[161] In recent years, light-sensitive liposomes (LSLs) that utilize
photosensitizing agents for drug release have been intensively studied. The Best lab has
synthesized PC analogue NB-PC with a photocleavable 2-nitrobenyzl group embedded
within an acyl chain.[162] Dose-dependent release has been reported with the amount
of NB-PC incorporated in PC-based liposomes when the system was exposed to light.
Through the work described in this dissertation, we sought to advance the
applications that can be accomplished using boronic acids by incorporating these moieties
into complex molecular architectures that can modulate their binding interactions and be
exploited to drive chemical and biological processes. To do so, we first developed a
boronic acid microplate assay to detect glycoprotein mucin-1 from cancer cell lysates
(Chapter two). We then developed boronic acid lipids that consist of a boronic acid
headgroup attached to a hydrophobic lipid scaffold that can be incorporated into a
liposomal drug delivery platform to drive binding interactions with carbohydrates and
glycoproteins and thereby enhance cellular surface glycans recognition and promote cell
entry (Chapter three and four). As discussed in the chapters below, by leveraging the
merits of both the boron-diol interaction and the intrinsic properties of lipids, our boronic
acids materials have proven to be effective agents for targeted drug delivery.
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2. A boronic acid assay for the detection of mucin-1 glycoprotein from
cancer cells
The scientific data used in this chapter has been published by the authors:
Xiaoyu Zhang, Shiqiang Zhang, Seung Joon Baek, and Michael D. Best.
ChemBioChem. 2017 Aug 17;18(16):1578-1582

2.1. Introduction
2.1.1 Overview
Cell surface glycoproteins are commonly aberrant in disease and act as biomarkers
that facilitate diagnostics.[163] Mucin-1 (MUC1) is a prominent example exhibiting
truncated glycosylation in cancer. We present a boronic acid microplate assay for
sensitive and high-throughput detection of such glycoproteins. Here, the immobilization
of biotin-boronic acid 2.1 onto streptavidin plates generates a multivalent surface for
glycoprotein recruitment and detection. We first validated the binding properties of 2.1
in solution through titrations with alizarin dye. Next, the microplate assay was explored
for HRP analysis as a proof-of-concept glycoprotein with chemiluminescence detection.
Finally, this platform was applied for the detection of MUC1 directly from MCF-7 cancer
cell lysates using an HRP-tagged antibody that targets the cancerous form of this
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glycoprotein. Sensitive dose-dependent detection of MUC1 was observed, showcasing
the efficacy of this platform for detecting disease- associated glycoproteins.

2.1.2 Cancer-associated membrane glycoprotein mucin-1
Membrane glycoproteins play critical roles in cell surface binding interactions that
control key physiological and pathophysiological processes. Many of these cell surface
glycans are aberrantly expressed on diseased cells, and thus act as important biomarkers
for disease onset and expression that can be exploited for diagnostic applications.
A prominent example of this phenomenon involves mucin-1 proteins, which
contain a transmembrane domain for anchoring to cell membranes as well as an
extracellular domain that is heavily glycosylated. Mucin-1 (MUC1), also known as CA15-3,
is a type I transmembrane protein with a heavily glycosylated extracellular domain that
extends up to 200–500 nm from the cell surface.[164, 165] Physiologically, the extended
negatively charged sugar branches of mucin-1 provide a barrier and anti-adhesive
protection to the underlying epithelia from desiccation, pH changes, pollutants and
microbes.[166, 167]
Mucin-1 has two peptide fragments: the long N-terminal subunit and the shorter
C-terminal subunit associated through stable hydrogen bonding.[168] Mature functional
mucin-1 is heavily O-glycosylated and moderately N-glycosylated.[169] It’s interesting to
note that tumor-associated mucin-1 differs from normal mucin-1, both in its biochemical
features and in its cellular distribution. Normally expressed mucin-1 contains heavily
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branched core 2 O-glycans, which mainly consist of galactose (Gal) and Nacetylgalactosamine (GalNAc). However, mucin-1 found in breast cancer cells contains
mostly the core 1 O-glycans, which mainly consist of Gal, GalNAc and N-acetylglucosamine
(GlcNAc).[170] This change is due to the deactivation of core 2 β6-GlcNAc-transferase.[171]
Another profound variation of glycosylation is the high level of sialylation in tumorassociated mucin-1, which results in the premature termination of chain elongation and
formation of truncated sugar branches.[172] It is hypothesized that the overexpression of
α2,3- and α2,6-sialyl-transferase is responsible for increased sialylation.[173]
Mucin-1 glycoproteins are associated with various forms of cancer including
breast, colon, ovarian, lung and pancreatic, and exhibit both abnormal expression and
glycosylation.[171, 174-179] As a matter of fact, truncated glycan chains are seen in
cancerous cells that terminate in T and Tn antigens and increased sialic acid. While these
variations associated with cancer provide an opportunity for diagnostic purposes,
complex glycoproteins are notoriously difficult to analyze using simple assays. Indeed,
mucin-1 is difficult to detect using traditional assays including gel electrophoresis and
Western Blotting due to its large size, transmembrane properties and varying
glycosylation pattern.

2.1.3 Boronic acid sensors for carbohydrates
Boronic acid units have been effective in the development of sensors for
carbohydrates through the reversible formation of boronate esters in the binding of diol
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moieties on glycans.[180-191] However, individual boronic acid hosts typically exhibit low
binding affinities towards carbohydrates in aqueous solution due to solvent competition.
This can be overcome through the use of multivalent boronic acid-presenting surfaces, in
which the synergistic effect of the binding of multiple glycans to binding groups can
dramatically enhance the binding affinity.[192-199] Boronic acids exhibit varying affinities
for different sugar units depending upon charge and diol orientation, and indeed the sialic
acid moiety of cancer-associated mucin-1 is among those that bind with the highest
affinity.

2.1.4 Microplate assays
Microplate and microarray assays provide an effective means for convenient and
high-throughput detection of biomolecules directly from complex biological
samples.[200-212] These platforms rely upon the ability to recruit biological molecules to
surface-immobilized ligands, followed by the detection of bound proteins. Often,
antibody-based detection is exploited, which benefits from the strong affinity and
selectivity of these reagents for particular proteins, and indeed specific forms of the
protein associated with the disease (ie sequence, posttranslational modification, etc.).
Finally, antibody-based utilizing chemiluminescence signal transduction benefits from
high sensitivity and convenience. For these reasons, we set out to develop a boronic acidbased microplate assay for glycoproteins, with mucin-1 as a significant initial target. We
envisioned that the immobilization of boronic acid moieties onto microplate surfaces
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would produce a dense clustering that would result in high affinity binding interactions
with glycoproteins,[196, 197] and that chemiluminescence-based signaling would enable
the sensitive detection of target disease-related proteins.
In order to develop a high-throughput assay for the detection of the cancerassociated glycoprotein mucin-1, we first set out to adapt the boronic acid sensor
platform for use within the context of a surface-based assay. For this purpose, a strategy
for the immobilization of the boronic acid sensing unit was needed. We and others have
previously exploited streptavidin-coated microplates and microarray slides as beneficial
surfaces for the non-covalent immobilization of binding moieties through the strong noncovalent streptavidin-biotin interaction in a manner that limits non-specific binding
interactions.[213-216] Thus, we elected to pursue a boronic acid-biotin conjugate for the
deposition of the sensing unit onto these surfaces.

2.2 Design and synthesis of biotin-boronic acid conjugate

The design and synthesis of boronic acid-biotin 2.1 used in this study is depicted
in Figure 2.1. This compound contains a biotin moiety for immobilization onto
streptavidin-coated surfaces as well as a boronic acid for the capture of glycan-containing
proteins and molecules. An ethylene glycol tether was introduced between these two
units to space the binding group from the derivatized surface. An ortho(alkylaminomethyl)phenylboronic acid unit was incorporated since the phenylboronic
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acid unit is known to stabilize boronic acid group and deter oxidation while the
aminomethyl group has been used to enhance carbohydrate binding affinity, particularly
at lower pH closer to physiological conditions.[217, 218] In the synthesis of 2.1,
phenylboronic acid 2.2 was first coupled to mono-Boc protected linker 2.3, which was
synthesized from the corresponding diamine precursor, through a reductive amination.
The remaining free amine of the product, 2.4, was then coupled to biotin succinimidyl
ester 2.5 to yield 2.1.

2.3. Initial validation of boronic acid binding properties with alizarin dye

Following the synthesis of 2.1, we next set out to analyze binding interactions with
this molecule through titration with the dye alizarin, which undergoes a shift in
photophysical properties upon binding to boronic acids through its catechol moiety.[219]
To do so, we first performed UV/Vis absorbance experiments in which we titrated a
solution of the dye with boronic acid 2.1 and observed the expected shift in absorbance
properties, with the lmax increasing from ~ 430 nm to 470 nm. This is shown in the form
of both a spectral overlay (Figure 2.2A) and a plot of intensity at 470 nm (Figure 2.2B).
Additionally, a fluorescence titration was performed through excitation at 450 nm. This
also led to the expected increase of fluorescence at ~600 nm, as indicated by spectral
overlay (Figure 2.2C) and a plot of emission at 592 nm (Figure 2.2D). Collectively, these
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titrations show that compound 2.1 binds to alizarin red S as expected for a boronic acid
sensor.

2.4 Boronic acid microplate assay for mucin detection

We next moved to implement boronic acid-biotin conjugate 2.1 for a surfacebased assay for glycoproteins as depicted in Figure 2.3. Here, the biotin moiety is
exploited to immobilize this molecule onto the surface of streptavidin-coated microplates.
This creates a high density boronic acid surface so as to enhance the binding affinity
towards glycoproteins through the formation of multivalent binding interactions.[202,
220-223] This is critical for the formation of complexes with sufficient stability for
detection purposes, particularly since individual boronic acids exhibit relatively low
affinities for monosaccharides. We first chose to test this platform for the detection
horseradish peroxidase (HRP), which is commonly used as a test case for the detection of
glycoproteins. HRP has been found to contain significant carbohydrate composition
including N-acetylglucosamine (GlcNAc), mannose, fucose and xylose units composing the
complex oligosaccharides.[224, 225] The choice of HRP also facilitates signal transduction,
as the protein can be used to catalyze the excitation of luminol, resulting in
chemiluminescence indicating the presence of protein bound to the surface. Thus, these
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initial studies do not require the HRP-tagged antibody depicted in Figure 2.3 that is
necessary for the detection of mucin-1.
For HRP studies, separate wells of 96-well streptavidin-coated microplates were
coated with uniform solutions containing 200 nM concentrations of boronic acid-biotin
conjugate 2.1 and washed to remove unbound molecules. Next, the functionalized
surface was treated with solutions of HRP of varying concentrations ranging from 0 - 100
µM, and again washed to remove unbound protein. Finally, the presence of bound protein
was evaluated using the Pierce supersignal ELISA femto maximum sensitivity substrate kit.
As can be seen in Figure 2.4A, a dose-dependent response in chemiluminescence was
observed relative to the amount of treated protein. Negative controls in which wells were
not treated with 2.1, but the assay was otherwise run in the same manner, yield
essentially no signal (data not shown). These results indicate the efficacy of this platform
for the binding and detection of glycoproteins.
Following this proof-of-concept, we set out to apply the boronic acid surface assay
to the detection of cancer-associated mucin-1. Purified mucin-1 protein is difficult to
access in a form in which glycosyation patterns are understood. Therefore, we turned our
attention to the detection of mucin-1 from cancer cell lysates, which was also preferable
for performing the analysis in a complex biological environment towards diagnostic
applications. For this, MCF-7 breast cancer cells were selected due to elevated
presentation of mucin-1. The assay was performed as previously described and illustrated
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in Figure 2.3, except microplates were treated with varying concentrations of MCF-7
lysate, followed by treatment with an HRP-tagged anti-MUC-1 SM3 antibody, with washes
in between each step. This antibody is designed to target the under-glycosylated form of
mucin-1 found in cancer cells and shows minimal binding affinity towards normal mucin1 glycoproteins. As can be seen in the chemiluminescence results shown in Figure 2.4B,
we once again obtained a dose-dependent response to treated cell lysate. We additionally
ran a negative control in this study in which wells were not treated with 2.1, but the assay
remained the same otherwise. These wells led to no signal, as shown in Figure 2.4B,
demonstrating that the boronic acid sensor 2.1 is needed for glycoprotein recruitment
and detection. This validates the detection of cancer-associated mucin-1 directly from
cancer cells using this platform.

2.5 Summary and future outlook
The described boronic acid assay provides a convenient and promising platform
for the rapid detection of disease-associated glycoproteins directly from biological
samples. The surface immobilization of the boronic acid binding moiety provides a
multivalent binding surface designed to increase the affinity towards complex
glycoproteins, thereby enabling a wash-off detection assay. The results show that both
purified proteins (HRP) and proteins within cell lysates (mucin-1) can be bound and
detected. The assay is expected to be generalizable based on the availability of antibodies
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against different disease-associated glycoproteins, and since this signal transduction
method can be used in conjunction with antibodies that bind to specific forms of the
protein (sequence, glycosylation, etc.) associated with disease states. Overall, this assay
overcomes significant challenges associated with the detection and characterization of
complex glycoproteins, and provides a promising means for analyzing these complex
biomolecules in a manner that is amenable to diagnostic application.

2.6 Material and method

General. Reagents and solvents were generally purchased from Acros, Aldrich or Fisher
Scientific

and

used

as

received.

tert-Butyl

(3-(2-(2-(3-

aminopropoxy)ethoxy)ethoxy)propyl)carbamate (2.3)[226] and biotin-succinimidyl ester
(2.5)[227] were synthesized as described previously. Dry solvents were obtained from a
Pure Solv solvent delivery system purchased from Innovative Technology, Inc. Column
chromatography was performed using 230–400 mesh silica gel purchased from Sorbent
Technologies and C18 (17%) reverse phase SPE columns (6ml, 2g) from Silicycle. NMR
spectra were obtained using Varian Mercury 300 or 500 MHz spectrometers. Mass
spectra were obtained with JEOL DART-AccuTOF or Applied Biosystems/ QStar Elite
HPLC—QTOF spectrometers. UV-vis absorbance titration experiments were performed
using an Evolution 600 UV-vis instrument from ThermoFisher Scientific. Fluorescence
titration

experiments

were

performed
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using

a

Cary

Eclipse

Fluorescence

Spectrophotometer from Agilent Technologies. Chemiluminescence and fluorescence
microplate studies were performed using a Synergy 2 Multi-Detection Microplate Reader
from BioTek Instruments, Inc. Pierce Streptavidin Coated 96-Well Plates and SuperSignal
Chemiluminescent Substrates were purchased from ThermoFisher Scientific. Type VI
Peroxidase from horseradish was purchased from SigmaAldrich. Mouse monoclonal
MUC-1 Antibody (SM3) tagged HRP-conjugate was purchased from Novus Biologicals.
Water for binding studies was purified using a Milli-Q filtration system. Data were plotted
and curve-fitted using SigmaPlot. All plots represent the average of at least 3 experiments
with error bars included +/- the standard error for each set of measurements.

Synthesis
(2-(19,19-dimethyl-17-oxo-6,9,12,18-tetraoxa-2,16-diazaicosyl)phenyl)boronic

acid

(2.4)
2-Formylphenylboronic acid (2.2, 0.258 g, 1.72 mmol) was dissolved in 20 mL of a mixture
of ethanol/toluene (90:10) and then amine 2.3 (0.5 g, 1.56 mmol) was added. A DeanStark trap was fixed to the reaction vessel and filled with 10 mL of the same solvent
mixture. The reaction was then allowed to stir for 16 h at 100 oC. Next, the reaction was
cooled using an ice bath. Sodium borohydride (0.118g, 3.12mmol) was then added slowly,
after which the reaction mixture was allowed to stir for 2 h at 0 oC. The solvent was next
removed through rotary evaporation and the resulting crude was purified using C18(17%)
reverse phase solid phase extraction (SPE) column chromatography with a gradient
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water/methanol solvent system. Compound 2.4 was obtained as a pale yellow gel (0.254
g, 0.56 mmol, 36% yield).
1

H NMR (300MHz, MeOD): δ 1.42 (s, 9H), 1.66-1.74 (p, 2H J=6Hz), 1.74-1.83 (p, 2H, J=9Hz),

2.65-2.69 (t, 2H, J=6Hz), 3.08-3.13 (t, 2H, J=9Hz), 3.31-3.34 (t, 2H, J=6Hz), 3.46-3.60 (m,
12H) 3.73 (s, 2H), 7.29-7.33(m, 4H) DART-MS [M+H]+: calcd for C22H40BN2O7 455.2929.

(2-(17-oxo-21-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-6,9,12trioxa-2,16-diazahenicosyl)phenyl)boronic acid (2.1)
Amberlyst® 15 resin (2.5 g) was soaked in methanol overnight. Next, this resin was
neutralized by soaking in 20 mL ammonia saturated methanol solution for 24h, followed
by a wash with 75mL 3M hydrochloric acid in 50% methanol solution. Finally, the resin
was washed with 25mL methanol, 25mL tetrahydrofuran and 25mL dichloromethane.
Compound 2.4 (0.1g, 0.22mmol) was dissolved in 5mL of anhydrous methanol, followed
by the addition of the cleaned Amberlyst® 15 (0.5g). The reaction was allowed to stir
overnight. Next, the reaction mixture was filtered and the solvent was removed by
rotatory evaporation. Purification of the deprotected amine was performed using
C18(17%) reverse phase SPE columns with a gradient water/methanol solvent system,
which yielded a pale yellow oil (0.070 g) that was passed onto the next step without
further purification. This was dissolved in 2 mL dry DMF and distilled triethylamine (Et3N,
0.03 mL, 0.22 mmol) and biotin succinimidyl ester (2.5, 0.075 g, 0.22 mmol) were added.
The reaction was then allowed to stir overnight at rt, after which the solvent was removed
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by rotatory evaporation. Compound 2.1 was purified using C18(17%) reverse phase SPE
column chromatography with a water/methanol gradient solvent system. The product
obtained as pale yellow oil (0.024 g, 21% yield).
1

H NMR (500MHz, MeOD): δ 0.87-0.97 (m, 1H), 1.28 (s 2H), 1.37-1.48(t, 3H,J=15Hz), 1.55-

1.76(m, 6H), 1.96-2.04 (p, 10H), 2.16-2.21 (t, 2H, J=15Hz), 2.64-2.67 (m, 1H), 2.71-2.72 (m,
1H), 2.89-2.93 (dd, 1H, J=5Hz), 3.00-3.05 (t, 2H, J=10Hz), 3.16-3.28 (m, 3H), 3.38-3.50 (m,
5H), 3.60 (s, 3H), 3.63-3.67 (t, 2H, J=10Hz), 4.04( s, 2H), 4.27-4.32 (m,1H), 4.46-4.50 (m,
1H), 7.13-7.21 (m, 2H), 7.42-7.44 (m, 2H).

13

C NMR (500MHz, MeOD): δ 25.47, 26.07,

28.10, 28.39, 28.72, 29.02, 31.65, 35.42, 36.39, 39.62, 46.19, 48.43, 53.57, 55.59, 60.20,
61.96, 68.45, 69.75, 69.86, 69.99, 70.05, 70.09, 126.24, 126.92, 164.66, 174.49. ESI-MS
[M+H]+: calcd for C27H46BN4O7S 581.318, [M+H-H2O]+: calcd for C27H44BN4O6S 563.3074
found 581.2982, 563.2924 [M+H-H2O]+.

Fluorescence and absorbance binding studies of boronic acid and ARS.
2 mL of a 100µM solution of alizarin in methanol was added to an empty cuvette. This
was titrated with a solution containing alizarin (100µM) and biotinylated boronic acid 2.1
(4.1 mM), which was added in 10 µL increments until the concentration of boronic acid
was 5 times as much as the concentration of alizarin. Absorbance and fluorescence
intensities were measured after each titration. Absorbance intensities were scanned from
200 to 700 nm. The excitation wavelength for fluorescence titrations was set at 450 nm
and fluorescence intensities were measured from 500 to 700nm. Each study was repeated
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at least three times.

Microplate HRP binding studies.
Peroxidase from horseradish Type VI was purchased from Sigma Aldrich ³ 250 units/mL
(U/mL). A stock solution of this protein of ~100 U/mL was prepared in wash buffer. The
wash buffer used in this study consisted of 10mM PBS at pH 8.0 with 0.01% Tween 10.
Experiments were performed in black 96-well microplates. First, all wells to be used were
incubated with 200 µL of the wash buffer for 30 min. After removing the wash buffer, to
each well was added 100 µL of a 200 nM solution of boronic acid-biotin 2.1 in wash
buffer. Solutions were incubated for 1 h, removed, and the wells were washed three times
with 250 µL wash buffer for 5 min each. Next, solutions of varying concentrations of
horseradish peroxidase (0, 1, 2, 4, 8, 10, 15, 20, 40, 80, and 100 U/mL) in wash buffer were
added into separate wells. These solutions were incubated for 1 h, removed, and the wells
were washed three times with 250 µL of wash buffer for 5 min. Chemiluminescence
detection of surface-bound HRP was next performed using supersignal ELISA femto
maximum sensitivity substrate. For detection, a 1:1 mixture of the substrate and peroxide
solutions was prepared, and 100 µL of the resulting solution was added to each well and
mixed with a multichannel pipetter. The microplate was then immediately placed in a
microplate reader, and chemiluminescence was repeatedly measured using a 440nm with
a bandpass of 20 nm filter for 10 min. Data were plotted and curve-fitted using SigmaPlot.
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Plots represent the average of at least 3 experiments with error bars included +/- the
standard error for each set of measurements.

MCF-7 cell lysate preparation
Human breast cancer MCF-7 cells were purchased from American Type Culture Collection
(Manassas, VA). Cells were cultured in Dulbecco's modified Eagle medium (DMEM).
Culture media was supplemented with 10% FBS, 100 U/ml penicillin, and 100 mg/ml
streptomycin, and culture cells were maintained at 37oC under a humidified atmosphere
of 5% CO2. For the cell lysate, MCF-7 cells were grown to 60- 80% confluence in 6-cm
plates. Total cell lysates were then isolated using RIPA buffer (1×PBS, 1% NP-40, 0.5%
sodium deoxycholate, 0.1% SDS) supplemented with protease inhibitors (1 mM PMSF, 5
µg/mL aprotinin and 5 µg/mL leupeptin) and phosphatase inhibitors (1 mM Na3VO4 and
1 mM NaF). The cell was sonicated 3 times. Protein concentration was determined to be
0.148 mg/mL by the BCA protein assay (Pierce, Rockford, IL), using BSA as the standard.

Microplate binding studies of MUC1 in MCF-7 cell lysate.
The wash buffer used in this study consisted of 10 mM PBS at pH 8.0 with 0.05% Tween
10. Black streptavidin- coated 96-well microplate wells were incubated with 200 μL of the
wash buffer for 30 min. After removal of wash buffer, 100 μL of a 200 nM solution of
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biotin-boronic acid 2.1 in water was added into different rows. A negative control was
also run in which wells were not treated with boronic acid 2.1, but otherwise experiments
were run the same. After 1 h of incubation, these solutions were removed, and the wells
were washed three times with 250 mL wash buffer for 5 min. MCF-7 cell lysate (0.148
mg/mL) was diluted 50-fold into wash buffer to produce a stock solution of 2.96 μg/mL.
Next, aliquots of this stock lysate (0, 1, 3, 5, 6, 7, 8, 9, 10, 12, 15, and 20 μL) were diluted
into wash buffer to a total volume of 100 μL, producing solutions of 0, 29.6, 88.8, 148,
178, 207, 237, 266, 296, 355, 444, and 592 ng/mL. These solutions were added to separate
wells of the microplate functionalized with 2.1. After 1 h of incubation, these solutions
were removed, and the wells were washed with 250 μL wash buffer three times for 5 min
each. HRP- tagged MUC1 antibody was diluted with wash buffer in a 1:500 ratio according
to manufacture instructions (from 0.1 mg/mL to 200 ng/mL). Then, 100 μL of the resulting
solution was added to each well. After 1 h of incubation, these solutions were removed,
and the wells were washed three times with 250 μL for 5 min each. Finally,
chemiluminescence detection of the HRP anti-MUC1 antibody was next performed using
supersignal ELISA femto maximum sensitivity substrate. For detection, a 1:1 mixture of
the substrate and peroxide solutions was prepared, 100 μL of the resulting solution was
added to each well, and solutions were mixed using a multichannel pipetter The
microplate was then immediately placed in a microplate reader, and the
chemiluminescence was repeatedly measured using a 440nm with a bandpass of 20nm
filter for 10 min.
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3. Boronic acid liposomes for cellular delivery and content release driven
by carbohydrate

The scientific data used in this chapter has been published by the authors:
Xiaoyu Zhang, Daiane S. Alves, Jinchao Lou, Shelby D. Hill, Francisco N.
Barrera and Michael D. Best. Chem. Commun., 2018, 54, 6169

3.1 Introduction
Liposomes have emerged as sophisticated carriers for delivering therapeutic
cargo.[71] Indeed, liposome-based drug delivery platforms have been approved by the
FDA and many more are in the late-stage of clinical trials.[228] To advance liposomal drug
delivery, two important areas of research include the enhancement of cell infiltration by
liposomes, and the ability to control cargo delivery by triggering the release of contents.
For the former, unnatural cationic lipids such as 1,2-dioleoyl-3-trimethylammonium
propane (DOTAP) or lipids conjugated to cell penetrating peptides (CPPs), such as
octaarginine (R8), are commonly used to infiltrate membranes.[229, 230] However, these
cationic lipids commonly exhibit significant toxicity.[231] Regarding triggered release,
approaches exploiting both active and passive stimuli, such as light, redox, pH, enzymes
and temperature have been explored, but there are drawbacks in each case.[109, 232,
233] Drawbacks of passive release include the minimal variations that are exploited for
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selective release, such as the slight increase in acidity in cancer cells (pH ~ 6.5-6.9)
compared to healthy cells (pH ~ 7.2-7.4).[234, 235] Active release protocols are hindered
by challenges in delivering external stimuli, such as poor tissue penetration using lightinduced release. Herein, we report boronic acid liposomes as a means for enhancing both
cell infiltration and content delivery based on carbohydrate binding interactions.
Aberrant glycosylation patterns, both in terms of carbohydrate composition and
abundance,[236, 237] are linked with diseases such as oncogenic transformation. For
example, glycosyltransferase dysregulation leads to increased sialylation of truncated
gangliosides and overexpressed complex β-1,6-branched N-linked glycans on human
melanoma cells.[238, 239] Such cell-type specific complex glycan alternations can provide
a handle for selective cell targeting and delivery. The boronic acid molecular recognition
unit has been extensively used to bind and separate carbohydrates through reversible
formation of boronate esters.[183, 188, 190] However, biological application of this
sensing group is challenged by the relatively low binding affinity in aqueous media. This
can be overcome through multivalent binding interactions, in which avidity effects lead
to exponential enhancements in affinity.[194] Smith and co-workers have previously
shown that boronic acid lipids are effective at driving calcium-dependent liposome
fusion[240] and at enhancing the binding of cell membranes.[241] In this chapter, we
delve into the efficacy of boronic acid liposomes as a means to enhance both cellular
infiltration and targeted content release driven by carbohydrate binding.
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3.2 Design and synthesis of single-tailed and dual-tailed boronic acid

This project began with the design of boronic acid lipid conjugates to present this
recognition group on the surface of resulting liposomes. One such compound is lipid 3.1,
in which the boronic acid is directly attached onto an aminoglycerolipid scaffold. An
ortho-(alkylaminomethyl)phenylboronic acid binding unit was chosen since the phenyl
group is known to stabilize the boronic acid while the amino moiety enhances
carbohydrate binding affinity at physiological conditions.[217, 218] The synthesis of 3.1,
shown in Figure 3.1, began with racemic 3-aminopropane-1,2-diol (3.2), the amine of
which was first protected as a phthalimide in 3.3. Next, a Williamson ether synthesis was
used to introduce hydrophobic alkyl chains using. Ether-linked lipid chains were employed
to circumvent potential hydrolysis by lipase enzymes in vivo. The pthalimide was next
deprotected to produce 3.4, which was followed by a reductive amination reaction to
produce 3.1. We additionally designed, synthesized and studied single-chain boronic acid
lipid 3.5 analogous to a fatty acid (Figure 3.2). This alternative lipid exhibited similar
properties as 3.1 during release studies, with results reported in the sections below.

3.3 Fluorescence-based dye leakage assay
We first evaluated triggered release from liposomes containing 3.1 or 3.5
upon treatment with the polysaccharide heparin as a model carbohydrate. Heparin
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is an anticoagulant consisting of repeating disaccharide units of sulphated iduronic
acid/glucuronic acid and glucosamine residues, and has previously been shown to
bind to boronic acids in a multivalent manner.[242, 243] Additionally, heparin
sulfate proteoglycans have been implicated for driving the cellular entry of cationic
liposomes through binding interactions.[244] We initially examined the release of
hydrophobic contents from liposomes using a Nile red release assay, in which
liposomal solubilization of this insoluble dye gives way to fluorescence decreases
when the dye is released into aqueous solution and precipitates.[245, 246] A
cartoon depicting the release of both hydrophobic and hydrophilic contents is
shown in Figure 3.3.
Unilamellar liposomes composed of 0% to 25% of boronic acid lipid 3.1
doped into L-α-phosphatidylcholine (PC, mixed isomers) were first prepared with
Nile red included in the formulation. Hydration, freeze-thaw, sonication and
extrusion through 200 nm membranes were performed to generate liposomes
with uniform size. As seen in Figure 3.4A, titration of Nile red-loaded liposomes
with heparin led to a decrease in fluorescence in a manner that was dependent on
the percentage of boronic acid lipid 3.1 incorporated within the liposomes.
Specifically, control liposomes containing 0% of 3.1 showed minimal background
release of Nile red (~5% fluorescence decrease), while this decrease was
accentuated with increasing boronic acid lipids (5% 3.1, ~10% decrease; 10% 3.1,
~25%; and 20% 3.1, ~50%). The extent of release appeared to reach a plateau since
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20% and 25% of 3.1 in liposomes yielded similar results. Control Nile red release
and dynamic light scattering (DLS) studies in which compound 3.4 was instead
included within liposomes showed minimal change, indicating the necessity of the
boronic acid moiety of 3.1 (Figure 3.5). In addition, titration with horseradish
peroxidase (HRP) glycoprotein as an alternative model with different carbohydrate
composition[224, 225] also yielded greater release using liposomes containing 3.1
(Figure 3.6), indicating generality and ruling out simple electrostatic binding. These
data provide evidence that the boronic acid units presented on the liposomes bind
to carbohydrates, thereby triggering Nile red release. In addition, the thresholdtype response we observed suggests the formation of multivalent binding
interactions that we expect to play a key role in binding and release.[202]
We anticipated that liposome release would be driven by lipid
reorganization upon carbohydrate binding in a manner that perturbs membrane
bilayer packing to stimulate content release. To assess this hypothesis, DLS
experiments were conducted to probe for changes in the particle sizes of lipid
assemblies before and after heparin treatment (Figure 3.4B). These are reported
using an exponential scale. Here, the inclusion of 3.1 showed no effect on initial
liposome size. Upon treatment with heparin, liposomes containing 0 or 5% 3.1
exhibited minimal changes in size, which matches the slight decrease in Nile red
fluorescence observed during release studies. Significant increases in particle sizes
were detected following heparin addition to liposomes containing 10-20% of 3.1.
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Finally, DLS studies of PC liposomes containing either 0% or 10% of 3.1 also showed
no significant changes over the course of a week at room temperature (data not
shown), indicating that these liposomes are robust.
We next studied carbohydrate-induced release of the polar fluorescent dye
sulforhodamine B.[247] In this assay, the dye is encapsulated within the liposome
aqueous core at high concentrations such that it is quenched, and size exclusion
chromatography (SEC) is used to remove unencapsulated fluorophore. Dye release
then leads to an increase in fluorescence intensity in bulk solution (Figure 3.3). The
extent of dye release in this assay is often variable based on the amount of soluble
dye that is entrapped when liposomes form and the variability of liposome
concentrations obtained by SEC purification. Thus, we normalized dye release as a
percentage of total release caused by final treatment of the liposomes with the
detergent Triton X-100. This assay culminated in dose-dependent increases of
sulforhodamine B fluorescence based on the percentage of 3.1 incorporated in the
liposomes (Figure 3.7). These results indicate that boronic acid 3.1 is also effective
for triggered release of polar contents from liposomes, which is more challenging
as this requires that polar/charged molecules escape the hydrophobic membrane
barrier. Boronic acid lipids 3.1 and 3.5 exhibited very similar properties in both the
Nile red and sulforhodamine release studies, and thus the results for 3.5 are shown
in Figures 3.8 and 3.9. Similarities in these data suggest that the particular lipid
scaffold that anchors the boronic acid in the membrane is not critical for activity.
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Both lipids do possess ortho- (alkylaminomethyl)phenylboronic acid moieties
known to enhance binding affinity at physiological pH.[217, 218]

3.4 Scanning transmission electron microscopy studies
To further explore the issue of changes in assembly, scanning transmission
electron microscope (STEM) images were taken before and after heparin
treatment. Here, standard liposome images were observed for samples containing
10% of 3.1 initially, while heparin treatment resulted in much larger and complex
membrane assemblies (Figure 3.10). On the other hand, images of control PC-only
liposomes treated with heparin showed liposomes with sizes similar to untreated
samples. The DLS and STEM data provide evidence for lipid reorganization driven
by heparin binding only when 3.1 is present, which could be explained by
carbohydrate-promoted processes such as fusion, aggregation and/or the
formation of different supramolecular lipid assemblies.

3.5 Microplate assay to confirm carbohydrate binding
We next sought to verify that boronic acid liposomes bind to carbohydrates
to further justify that release may be caused by molecular recognition. A
microplate assay was used to assess the binding of fluorescent liposomes to a
commercially available heparin-biotin conjugate immobilized onto streptavidin47

coated microplates. We have previously used similar assays to study liposome and
lipid binding interactions.[248-250] Liposomes in this study contained either 0%
(control) or 20% of 3.1, 1% rhodamine-labeled phosphatidylethanolamine (Rd-PE)
as a fluorescent marker, with the remainder PC. The results (Figure 3.11) indicate
a significant enhancement in surface binding when 3.1 was present in the
liposomes, thereby validating the heparin-binding ability of liposomes containing
3.1. In an additional control, liposomes containing 3.1 yielded minimal signal when
heparin-biotin was not added (data not shown).

3.6 Cellular delivery studies of boronic acid liposomes
We next assessed the ability of lipid 3.1 to promote liposome cell entry.
Boronic acid liposomes were expected to bind to cell surface carbohydrates and
enhance proximity to plasma membranes, thereby boosting cell entry pathways
such as membrane fusion or pinocytosis (Figure 3.12A). Confocal fluorescence
laser scanning microscopy experiments were used to evaluate the delivery of
liposomes containing 0.08% of Rd-PE. Control liposomes with only PC and Rd-PE
were compared to study samples doped with 10% of 3.1. Liposomes were
incubated with A375 melanoma cells for one hour at 37°C, washed to remove
residual free liposomes, labelled with DAPI, fixed and mounted on glass slides for
imaging. Representative images are shown in Figure 3.12. Cells treated with
liposomes containing 10% of 3.1 yielded a dramatic enhancement in fluorescence
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(Figure 3.12C) compared to control liposomes lacking 3.1 (Figure 3.12B). These
results show that 3.1 is effective for driving liposomal cell entry. As an initial
assessment of toxicity, cells treated with liposomes containing 10% 3.1 and 0.08%
Rd-PE were observed to be healthy after incubation, while liposomes containing
15-20% of 3.1 with 0.08% Rd-PE led to observable toxicity effects including some
cytoplasmic shrinking and nuclear distortion, particularly at longer incubation
times, which may result from membrane disruption. While extensive studies are
required to assess the clinical viability of this platform, these results showcase
boronic acid lipid 3.1 as a promising agent for cellular delivery.

3.7 Summary and future outlook
In conclusion, we have found that liposomes containing boronic acid lipid 3.1
are effective for content release and cell entry driven by carbohydrate binding.
These liposomes could provide versatility by either delivering therapeutic cargo
directly via cell entry or by releasing contents upon in close proximity to cells, both
of which are likely to enhance delivery. While this provides a promising means for
general cellular delivery applications, it also opens up the possibility of selective
delivery to diseased cells based on the specific composition and abundance of cell
surface carbohydrates. In particular, boronic acid dimers have been reported that
exhibit selective binding to tumor markers such as sialyl Lewis X.[251] Future work
will be aimed at studying and enhancing cell type-specific cellular delivery using
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boronic acid moieties similar to these adapted for presentation on liposome
surfaces.

3.8 Materials and method

General experimental. Reagents and solvents were generally purchased from Acros,
Aldrich or Fisher Scientific and used as received. Heparin lithium salt from porcine
intestinal mucosa was purchased from Sigma-Aldrich, Inc. L-α-Phosphatidylcholine (mixed
isomers) and L-α-phosphatidylethanolamine-N-(lissamine rhodamine B sulfonyl)
(ammonium salt) were purchased from Avanti Polar Lipids, Inc. Dry solvents were
obtained from a Pure Solv solvent delivery system purchased from Innovative Technology,
Inc. Column chromatography was performed using 230–400 mesh silica gel purchased
from Sorbent Technologies. NMR spectra were obtained using Varian Mercury 300 or 500
MHz spectrometers. Mass spectra were obtained with JEOL DART-AccuTOF or Applied
Biosystems/ QStar Elite HPLC—QTOF spectrometers. Fluorescence titration experiments
were performed using a Cary Eclipse Fluorescence Spectrophotometer from Agilent
Technologies. Water for liposome preparation and trigger-release studies was purified
using a Milli-Q filtration system. Data were plotted and curve-fitted using SigmaPlot 13.
Dynamic Light scattering measurements were performed to study the size and stability of
liposomes using a Malvern Zetasizer Nano ZS instrument equipped with a He-Ne 633 nm
laser and a temperature controller at a scattering angle of 173°. All plots represent the
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average of at least 3 experiments with error bars denoting +/- the standard error for each
set of measurements.

Synthesis
(2-((dodecylamino)methyl)phenyl)boronic acid 3.5
2-Formylphenylboronic acid (0.89 g, 5.929 mmol) and triethylamine (1.09 g, 10.78 mmol)
were dissolved in 10 mL of a mixture of ethanol/ toluene (90:10) in a 50 mL roundbottomed flask and then dodecan-1-amine (1 g, 5.39 mmol) was added. A Dean-Stark trap
was fixed to the reaction vessel and filled with 10 mL of the same solvent mixture. The
reaction was then allowed to stir for 16 h at 100°C, and then cooled using an ice bath.
Sodium borohydride (0.82 g, 21.56 mmol) was then added slowly, after which the reaction
mixture was allowed to stir for 2 h at 0°C. The solvent was next removed through rotary
evaporation and the resulting crude was purified through silica gel column
chromatography with an increasing gradient of ethyl acetate/ hexane solvent system
from 25% to 100% and then flushed with 100% methanol. The product was then dissolved
in dichloromethane and filtered. Then, dichloromethane was removed under reduced
pressure to yield compound 3.5 as a white gel (1.29 g, 4.03 mmol, 85% yield). 1H NMR
(300 MHz, Chloroform-d) δ 7.53 – 7.41 (m, 2H), 7.35 – 7.28 (m, 2H), 3.88 (s, 2H), 2.67 (t,
2H, J = 6.0 Hz), 1.63 (p, 2H, J = 4.5 Hz), 1.30-1.24 (m, 18H), 0.88 (t, 3H, J = 6.0 Hz). 13C NMR
(126 MHz, Chloroform-d) δ 140.6, 130.4, 127.3, 126.7, 122.7, 53.5, 49.8, 47.7, 29.5, 29.4,
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29.2, 27.0, 22.5, 13.9. 11B NMR (160 MHz, Chloroform-d) δ 13.65. ESI-MS [M+H]+: calcd
for C19H35BNO2 320.2761, found: 320.2318.

2,3-bis(hexadecyloxy)propan-1-amine 3.4
2-(2,3-dihydroxypropyl) isoindoline-1,3-dione (3.3) was synthesized as described
previously.[252] This compound (260 mg, 1.17 mmol) was dissolved in 15 mL of anhydrous
DMF in a 50 mL round-bottomed flask. Sodium hydride (NaH, 112 mg, 4.68 mmol) was
added to this solution under a nitrogen stream. The reaction was allowed to stir at -20°C
(acetone ice bath) for 15 min and then at rt for 10 min at which point the solution turned
yellow. 1- Bromohexadecane (1.56 g, 4.68 mmol) was added to the solution, which was
then stirred at rt overnight. The reaction was then quenched by adding 1 mL of water,
and the solvent was removed under reduced pressure. The crude was extracted with
dichloromethane from saturated sodium chloride solution (3 x 50 mL). The organic layer
was dried with magnesium sulfate, filtered and concentrated to yield crude product as
the phthalimide-protected version of 3.4. Without further purification, the reaction crude
was dissolved in 10 mL ethanol along with 2 mL hydrazine monohydrate and heated to
reflux overnight at 70°C. The solvent was then removed under reduced pressure. Thin
layer chromatography (TLC) using 10% methanol/ dichloromethane as eluant identified
the product spot with a Rf value of 0.4 and Ce/Mo and nihydrin stain active. The crude
was purified by column chromatography using a gradient solvent system of 2-10%
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methanol/dichloromethane to yield amine 3.4 as a pale yellowish oil (221 mg, 35% (over
2 steps)). 1H NMR (500 MHz, Chloroform-d) δ 3.66 – 3.57 (m, 1H), 3.51 – 3.27 (m, 5H),
3.10-3.15 (m, 1H), 2.90 – 2.76 (m, 2H), 1.52 (p, 4H, J = 4.5Hz), 1.36 – 1.17 (m, 52H), 0.88
(t, 6H, J = 6.0 Hz). 13C NMR (126 MHz, Chloroform-d) δ 71.9, 71.0, 70.4, 42.7, 31.9, 30.9,
30.1, 29.7, 29.4, 26.1, 22.7, 14.1. DART-MS [M+H]+: calcd for C35H74NO2 540.5719, found:
540.5948.

(2-(((2,3-bis(hexadecyloxy)propyl)amino)methyl)phenyl)boronic acid 3.1
2-Formylphenylboronic acid (55 mg, 0.37 mmol) and triethylamine (51 µL, 0.37 mmol)
were dissolved in 5 mL toluene in a 50 mL round-bottomed flask and then amine 3.4 (100
mg, 0.18 mmol) was added. A Dean-Stark trap was fixed to the reaction vessel and filled
with 10 mL toluene. The reaction was then allowed to stir for 16 h at 100°C. Next, the
reaction mixture was cooled to 0°C in an ice bath and sodium borohydride (28 mg, 0.74
mM) was added slowly, after which the reaction mixture was allowed to stir for 2 h at 0°C.
The solvent was next removed through rotary evaporation and the resulting crude was
purified with an increasing gradient of methanol/ dichloromethane solvent system from
10% to 100%. Boronic acid lipid 3.1 was obtained as a pale yellow oil (33.9 mg, 28% yield).
1

H NMR (500 MHz, Chloroform-d) δ 7.84-7.77 (m, 2H), 7.71-7.64 (m, 2H), 4.06 (s, 2H), 3.90

– 3.81 (m, 2H), 3.80-3.75 (m, 1H), 3.63-3.56 (m, 2H), 3.54-3.46 (m, 2H), 3.44-3.38 (m, 2H),
1.51 (q, 4H, J = 3.5 Hz), 1.29-1.14 (m, 52H), 0.86 (t, 6H, J = 6.0 Hz). 13C NMR (126 MHz,
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Chloroform-d) δ 138.6, 130.6, 129.3, 128.5, 127.0, 121.0, 71.2, 65.2, 56.0, 51.3, 31.9, 29.6,
29.3, 26.8, 25.8, 22.7, 14.1, DART-MS [M+H]+: calcd for C35H74NO2 674.6259, found:
674.3933.

Nile red liposome release studies
Liposome preparation was initiated by weighing out samples of PC, boronic acid lipid 3.1
or 3.5, and Nile red in separate vials to make 32 mM PC, 5 mM BA lipids and 5 mM Nile
red stock solutions in ethanol-free chloroform. Phosphate-buffered saline (PBS, 2 mM, pH
8.0) was chosen as the buffer solution. Heparin lithium salt (10 mg) from porcine intestinal
mucosa was added into a 2.08 mL PBS buffer to make a 1,040 U/mL (ie 4.79 mg/mL) stock
solution. Benzyl alcohol (0.1%) was added in heparin stock to prevent bacterial growth as
suggested by manufacturer. After brief vortexing, the appropriate volumes of the stock
solution of each lipid component and Nile red were pipetted into a clean vial per
calculations on a 5 mM, 240 µL total lipid scale, to obtain the desired molar percentage
of each component. As an example, for liposomes composed of 10% 3.5 and 85% PC, 5%
Nile red, 31.9 µL PC stock (78.6 µg), 24 µL 3.5 stock (3.8 µg), and 12 µL Nile red stock (1.91
µg) were combined. After 30 seconds of vortexing, the chloroform solvent was dried with
a nitrogen stream, and the lipids were subsequently dried for at least 3 h under vacuum.
Then, the lipids were hydrated with 240 µL of PBS buffer, incubated on a 60°C water bath
for 3 sets of 20 min, with vortexing after each set. Liposomes then underwent freeze54

thaw cycles between a -80°C dry ice-acetone bath and a 60°C water bath for 10 cycles.
Vortexing at low speed was performed during each freeze-thaw cycle. Next, liposomes
were extruded through a 200 nm membrane filter for 21 passes using a LiposoFast
extruder (Avestin, Inc.), and then added to a fresh vial. DLS scans were performed to
confirm the formation of stable liposomes.For fluorescence-based release studies, 100 uL
samples of liposome vesicles were added into a sub-micro cuvette cell (Starna Cells, Inc).
After an initial fluorescence scan (excitation wavelength of 553 nm, emission wavelength
scanned from 560 nm to 580 nm), 0.5µL of heparin stock (0.52 U) was added into the
cuvette before each fluorescence scan, which was performed 20 times. Data presented
in plots indicate emission values at 621 nm. To account for the dilution caused by the
addition of heparin solution, blank samples were run by diluting liposomes with the same
volumes of water, which were subtracted from the study samples as follows. From the
observed fluorescence during the measurement period, a normalized release function
that describes the efflux over the period of the experiment was determined according to
the equation below to exclude buffer dilution, where F(tx) and F(bx) are the measured
fluorescence at titration times x with heparin and buffer accordingly, and F(t0) and
F(b0) are initial fluorescence for 2 different set:
1(23) 4 1(53)

% release = 1(26) 4 1(56) * 100
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STEM Imaging Studies
Liposome solutions (5 mM) containing either 0% or 10% of boronic acid lipid 3.1, and the
remaining portion consisting of PC (100% or 90%, respectively) were prepared as
previously described. One portion of liposomes (100 µL) was mixed with 10 µL of a 2,170
U/mL heparin stock as described for the Nile red release studies, and was then incubated
at rt for 30 min, while another aliquot was mixed with 10 µL PBS buffer solution and also
incubated at rt for the same amount of time. After that, both portions were diluted to
400 µM solutions with PBS buffer to reach ideal concentrations for scanning transmission
electron microscopy (STEM) studies. A drop (5−10 μL) from each solution was immobilized
onto separate carbon films supported by 200 mesh copper grids. The samples were
stained with 5% uranyl acetate for 1 h and then washed three times with distilled water
for 10 min and stored in a desiccator overnight prior to imaging. Images were collected
using a Zeiss Auriga operating in scanning transmission mode. The electron beam energy
was set at 30 KeV, and images were detected using an Everhardt-Thornley SE2 detector.

Sulforhodamine B liposome release studies
Stock solutions were initiated by weighing out samples of PC and boronic acid lipid 3.1 in
separate vials to generate separate 32 mM PC and 5 mM 3.1 or 3.5 solutions in ethanolfree chloroform. Phosphate-buffered saline (2 mM, pH 8.0) was chosen as the buffer
solution. Heparin lithium salt (10 mg) from porcine intestinal mucosa was added into 1mL
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PBS buffer to make 2,170 U/mL stock solution. Benzyl alcohol (0.1%) was added in heparin
stock to prevent bacterial growth as suggested by the manufacturer. Sulforhodamine B
sodium salt (116.1 mg) was dissolved in 10 mL PBS buffer to make s 20 mM stock solution.
After brief vortexing, proper volumes of each lipid stock solution were pipetted into a
clean vial per calculations on a 10 mM, 240 µL total lipid scale to obtain the desired molar
percentage of each component. As an example, for liposomes composed of 15% 3.5 and
85% PC, 63.8 µL PC stock (157.1 µg) and 72 µL 3.5 stock (11.5 µg) were added into a new
vial. After 30 seconds of vortexing, the chloroform solvent was dried with a nitrogen
stream, and the lipids were subsequently dried for at least 3 h under vacuum. Next, the
lipids were hydrated with 240 µL of the previously described sulforhodamine stock
solution and incubated on a water bath at 60°C for 3 sets of 20 min, with vortexing after
each set. Liposomes then underwent freeze-thaw cycling between a -80°C dry ice-acetone
bath and a 60°C water bath for 10 cycles. Vortexing at low speed was performed during
each freeze-thaw cycle. After that, liposomes were extruded through a 200 nm
membrane filter for 21 passes using a LiposoFast extruder (Avestin, Inc.) and then added
to a fresh vial. Next, liposomes were separated from unencapsulated dye using a
Sephadex G-50 size exclusion column (SEC). Liposomes came out in the first or second
fraction and were detected by the change in fluorescence upon treatment of an aliquot
with triton X-100. DLS scans were performed to confirm the formation of stable
liposomes. For fluorescence-based release studies, 100 µL liposome samples were added
into a sub-microcuvette cell (Starna Cells, Inc). After an initial fluorescence scan
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(excitation wavelength at 553 nm, emission wavelength scanned from 560 nm to 660 nm),
0.5 µL heparin stock (1.08 U) was added for each fluorescence measurement before
quenching by adding 1 µL 1% (v/v) Triton-X 100 in PBS to convert liposomes into mixed
micelles and trigger rhodamine release. Data presented in plots indicate emission at 606
nm. To account for the dilution caused by the addition of heparin solution, blank samples
were run by diluting liposomes with the same volumes of water, which were subtracted
from the study samples as follows. From the observed fluorescence during the
measurement period, a normalized release function that describes the efflux over the
period of the experiment was determined according to the equation below to exclude
buffer dilution where F(t), F(x) , F(0) are the fluorescence intensity measured after
adding Triton X-100, x addition time of heparin stock and initial fluorescence intensity,
1(2)– 1(3)

accordingly.% release = 81 − 1(2)– 1(6)< ∗ 100%

Microplate liposome-heparin binding studies
The wash buffer used in this study was 10 mM PBS at pH 8.0. 10 μg Heparin−biotin sodium
salt purchased for Sigma-Aldrich (~ 15000 kDa) was added into 10 mL PBS buffer to
prepare a 1 μg/mL stock solution. Liposome solutions (2 mM) consisting of 1% rhodamine
L-α-phosphatidylethanolamine (Rd-PE), either 0% or 20% of boronic acid lipid 3.1, and the
remaining portion consisting of PC (99% or 79%, respectively) were prepared as
previously described. Next, opaque streptavidin-coated 96-well microplate wells were
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washed with 250 μL buffer for 30 min. After removal of buffer, 100 μL of heparin−biotin
solution was added into study wells. Additional negative controls were run in which wells
were treated with the different liposome compositions, but not with heparin−biotin, and
experiments were otherwise run the same. After 1 h of incubation, these solutions were
removed, and the wells were washed three times with 250 μL wash buffer for 5 min. Next,
aliquots of liposomes were diluted into wash buffer to a total volume of 100 μL, producing
solutions of 0, 20, 40, 80, 100, 200, 400, 500, 600, 800, and 1000 μM. These solutions
were added to separate wells of the microplate functionalized with heparin. After 2h of
incubation, these solutions were removed, and the wells were washed with 250 μL wash
buffer three times for 5 min each. Finally, 100 μL of wash buffer was added to each well,
and the microplate was analyzed using a Biotek Synergy 2 microplate reader, and the
fluorescence intensity was repeatedly measured at excitation wavelength of 530 +/- 20
nm and emission wavelength of 590 +/- 20 nm.

Cell culture and fluorescence microscopy
Melanoma A375 cells, obtained from ATCC® (Manassas, VA), were cultured in a humidified
incubator under 5% CO2 in DMEM medium supplemented with 10% of Fetal Bovine
Serum, 50 U/mL penicillin, and 50 µg/ml streptomycin (Invitrogen). Two days prior to the
experiment, A375 cells were plated at a seeding density of 1 x 104 cells per well on a glass
coverslip. Liposomes containing 0.08% rhodamine L-α-phosphatidylethanolamine (Rd-PE)
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in the absence or presence of 10% of boronic acid lipid 3.1, with the rest of the liposome
consisting of PC were incubated with cells at a concentration of 1 mM for 1 h at 37°C.
Liposome preparation was conducted under similar conditions as described above, except
10 mM PBS pH 7.4 was used as the buffer. After incubation, cells were washed four times
with PBS containing 1 mM MgCl2 and 100 mM CaCl2 (PBS++), fixed for 30 min in 4%
paraformaldehyde and mounted with ProLong Diamond Antifade Mountant with DAPI
(Invitrogen). Images were acquired on a confocal laser scanning microscope (Zeiss LSM
710) with 63x objectives using Zen2 blue edition software. Contrast and brightness
settings were chosen so that all pixels were in the linear range. Images are the product of
fourfold line averaging.
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4. Bisboronic acid liposomes for selective binding of sialic acids and
enhanced cancerous cell delivery
4.1 Introduction
4.1.1 Overview
In the previous chapter, lipids with a single boronic acid headgroup were
synthesized and studied for carbohydrate triggered release and enhanced cellular
delivery. In this chapter, more sophisticated lipids containing two boronic acids were
developed with the goal of selective binding interactions with sialic acid-containing
carbohydrates that are often overexpressed on cancer cell surfaces. Here, we were
inspired by previous work in the field showing that rigid bisboronic acid compounds can
yield enhanced selectivity for particular carbohydrate targets. To translate this work for
liposome delivery, we designed and synthesized bisboronic acid lipids containing with a
small library of selected aromatic spacers to control the distance between the two
boronic acid units.[62] To study the carbohydrate-binding properties of bisboronic acid
liposomes, we first developed a three-component fluorescent competition assay using
Alizarin Red S to evaluate the binding affinity toward N-acetylneuraminic acid. Then,
liposomes containing bisboronic acid lipids were investigated in hydrophobic and
hydrophilic fluorescent dye triggered release study using the sialic acid-rich glycoprotein
mucin. Next, the most effective bisboronic acid lipid from these prior studies was chosen
for liposomal cell delivery experiments using fluorescence microscopy. In these studies,
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dose-dependent cell labelling was observed in melanoma cell lines based on the
percentage of bisboronic acid lipid within liposomes, which indicates the potential of
synthetic bisboronic acid lipids for selective drug delivery.

4.1.2 Structure, property and biological significance of sialic acid
As depicted in Figure 4.1, sialic acids compose a family of around 40 derivatives of
the nine-carbon sugar neuraminic acid, which is the unsubstituted form of this sugar that
does not exist in nature.[253-255] The most abundant sialic acid is N-acetylneuraminic
acid (Neu5Ac) where the amino group is acetylated. Due to the acidity of the neutral form
of this molecule (pKa = 2.6), the carboxyl group at position 1 is negatively charged under
physiological conditions.
Due to their size, hydrophilicity, acidity and its negative charge, sialic acids play
important roles in cellular and molecular recognition events.[256-258] These sugars can
bind and transport positively charged molecules (such as calcium ions (Ca2+)), and also
stabilize the conformations of enzymes or cell membranes proteins.[259] Perhaps the
most interesting feature of sialic acids is their presence in many oncofetal carbohydrate
antigens. It is well known that tumor cell surfaces are decorated with abnormal
glycosylation makeup in the form of overexpressed naturally occurring or
pathophysiological oligosaccharides.[260] It is estimated that there are as many as 109
sialic acid residues on multiple sialylated antigens per tumor cell.[261] The alteration, in
both structure and abundance, of sialic acids has been correlated with malignant and
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metastatic phenotypes in epithelial-derived cancers, such as gastric, colon, pancreatic,
liver, lung, prostate, and breast cancers.[262] The high level of sialylation has an immunosuppressive effect since it prevents cells from degradation by masking subterminal
galactose residues.[263] As a result, strategies that can target cells based on their sialic
acid expression may be beneficial for selective tumor diagnosis as well as treatment.
Due to the overexpression of sialic acids on diseased cells, significant effort has
gone into exploiting this phenomenon for the selective labeling of diseased cells. For
example, the Bertozzi lab reported a highly selective reaction of ketones with aminooxy
groups that can differentiate subtle modifications in sialoside metabolism and ultimately
enable selective delivery of magnetic resonance contrast reagents to tumor cells.[264]
The Peters lab designed and synthesized two novel lanthanide ion ligands consisting of
diethylenetriamine pentaacetic acid (DTPA)-bisamide that are capable of molecular
recognition of sialic acid residues by boronic functional moiety.[265] Djanashvili and
coworkers have demonstrated in vivo targeting based on the recognition of
overexpressed sialic acid by a phenylboronic acid-based imaging reporter in aid of low
molecular weight Gd complex.[266] As a major topic of this dissertation, a more in-depth
discussion of selective boronic acid materials for sialic acids is included in the section
below.
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4.1.3 Selective detection of carbohydrates using bisboronic acid materials
Initially demonstrated in the seminal work done by Yoon and Czarnik in 1992,
boronic acid-based materials can act as fluorescent sensors of carbohydrates.[47] In the
two decades since, the development of boron-based materials for monosaccharides,
polysaccharides and cell surface glycans has been a focus in carbohydrate research and
material science. The Shinkai group reported a landmark study describing a selective
glucose sensor 4.1 (Figure 4.2) with chiral binaphthol core and aminoboronate that uses
a photoinduced electron transfer (PET) signal transduction scheme.[267] This system can
differentiate between enantiomers of glucose and overcome the low affinity of single
boronic acid sensors for glucose at physiological pH by using a bisboronic acid. The
Singaram lab has developed a dye/quencher system using the anionic dye 8hydroxypyrene-1,3,6-trisulfonic acid trisodium salt (pyranine) and bisboronic acid
bipyridinium salt 4.2 for the selective binding of glucose.[268]
Besides the ability to recognize monosaccharides, boronic acid materials have
been explored for molecular interactions with cellular surface glycan in physiological
settings. Boronic acids can form boronate esters reversibly with polyol motifs on sugars
and selectivity towards certain carbohydrate can arise from the intrinsic orientation of
hydroxyl groups on the rigid carbocyclic skeleton. The biggest drawback of using boronic
acids is that they exhibit a prominent preference for binding furanosides, while possessing
low binding affinity towards hexopyranosides, which are the major components of cell
surface glycoconjugates.[269] To achieve selectivity towards pyranose sugars, the Hall lab
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reported a rationally designed library of synthetic receptors of type 4.3 containing a
peptide backbone that can act as both a hydrogen bonding donor or acceptor with two
benzoboroxole groups attached on diaminopropionic acid residues in the central amino
acid position.[59] The function and geometrical diversity of these structures are achieved
by twenty different natural and synthetic amino acids serving as spacers in the middle of
the peptide backbone and the acyl capping group consisting of a selection of twenty
carboxylic acids. Selectivity in the binding of the TF antigen disaccharide was discovered
upon screening a library of 400 peptidyl bis(boroxole) receptors using a competitive
enzyme-linked immunosorbent assay (ELISA) assay.
The Wang lab additionally developed a family of anthracene-based fluorescent
bisboronic acid sensors of type 4.4, for which a change in fluorescence intensity is caused
by boronic ester formation upon the binding of carbohydrates along with the masking of
the nitrogen lone pair of electrons.[62] Their diboronic acid compounds with the proper
spatial arrangement of the two boronic acid headgroups were pruned to multiple pairs of
diols and showed highly specific affinity for the target carbohydrate Sialyl Lewis X.
Other boronic acid-based compounds that are not bisboronic acids have also
shown selectively towards certain carbohydrate. For example, the Miyahara lab
developed a group of heterocyclic boronic acids possessing high affinity and selectivity
for

sialic

acids.[270]

Among

them,

5-boronopicolinic

acid

and

3-

propionamidophenylboronic acid have proven to be strong sialic acid-binders under
acidic pH conditions of hypoxic tumoral microenvironment.
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4.2 Design and synthesis of bisboronic acid lipids
In this project, we set out to develop bisboronic acid lipids that could translate
selective carbohydrate binding properties to a membrane environment as a means for
achieving the selective delivery of liposomes to sialic acid-presenting diseased cells.
Toward this end, the design and synthesis of bisboronic acid lipids is shown in Figure 4.3.
First, a Wulff-type type ortho-(alkylaminomethyl)phenylboronic acid unit was introduced
on the lipid scaffold. This was done through a reductive amination reaction between
dodecylamine 4.5 and (2-formylphenyl)boronic acid with the aid of a Dean-Stark trap to
remove water that is produced. Since the phenyl ring is known to stabilize the boronic
acid through hyperconjugation effects and the ammonium moiety (in the protonated
form of 3.5) serves as an electron withdrawing group, our synthetic boronic acids are
expected to possess increased Lewis acidity with lower pKa value while also exhibiting
higher affinities towards carbohydrates at physiological pH.[12]
As mentioned in the previous section, cancerous cell surfaces have aberrant
glycosylation patterns and overexpression of sialic acids is one of the signature features
of tumor cells. To achieve high selectivity for specific carbohydrates, our strategy was to
vary the identity and length of the linker connecting the two boronic acids backbone to
probe for selectivity towards sialic acids. For this purpose, compound 3.5 was treated with
aromatic dibromide compounds in the presence of potassium carbonate to give
bisboronic acid lipids 4.6a-e. As listed in Table 4.1, aromatic spacers with different length,
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rigidity and geometry that were used to link the two boronic acid lipids include o-xylene,
m-xylene, p-xylene, 2,6-dimethylnaphthalene and 4,4'-dimethyl-1,1'-biphenyl.

4.3 Competition assay of dye alizarin red s to analyze sialic acid binding
Following the synthesis of bisboronic acid lipids 4.6a-e, we developed a
competitive binding assay of boronic acids with the aid of fluorescent dye Alizarin Red S
(ARS) to evaluate their affinity towards sialic acid. N-Acetylneuraminic acid was chosen
as a representative carbohydrate model since it is the most predominant of the family of
sialic acids and can be found attached to many mammalian cells, human cells
included.[271] ARS has been used as a reagent to measure the concentration of boric
acid, since the active protons of the hydroxyl groups among hydroxyanthraquinone
compounds can form intra/intermolecular hydrogen bonds with ketones and result in
significant fluorescence quenching, with fluorescence restored when the catechol diol of
ARS binds to a boronic acid.[272-276]
The fluorescence intensity changes in this three-component system can be used
to measure the binding affinity of bisboronic acid lipids qualitatively and quantitatively.
As shown in Figure 4.4, two competing equilibria are present in the fluorescence assay
system. The first equilibrium is between the boronic acid and the fluorescent indicator
ARS, which can be directly measured by an increase in fluorescence caused by boronate
formation. When Neu5Ac is added to the system, the second equilibrium involves the
binding of the bisboronic acid lipid to the added carbohydrate, which occurs through
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displacement of the previously bound ARS and leads to a decrease in fluorescence
intensity through ARS release and protonation.
A representative full titration curve for treatment of m-xylene bisboronic acid lipid
4.6b with ARS and then Neu5Ac is shown in Figure 4.5. To overcome the solvent
incompatibility of hydrophobic bisboronic acid lipid 4.6b and hydrophilic guests ARS and
Neu5Ac, bisboronic acid lipids were incorporated into PC-based liposomes in PBS buffered
aqueous environment. Liposomes were prepared using conventional thin layer film
method using a standard protocol including hydration, free-thaw and size extrusionFirst,
nine portions of 0.5 μL of a 2 mM ARS solution were added to 100 μL of a 5mM solution
of PC-based liposomes containing 0 or 10% bisboronic acid lipids 4.6b and fluorescence
intensity was measured after adding each aliquot of ARS. Following this, Neu5Ac was
added to competitively bind to bisboronic acid liposomes by displacing ARS. In this phase
of the experiment, nineteen 0.5 μL aliquots of a 50mg/mL Neu5Ac solution were added
to the system, which led to a drastic decrease in fluorescence intensity. At the endpoint,
the total amount of liposomes with m-xylene bisboronic acid lipid 4.6b, ARS, and Neu5Ac
were 5 × 10-7mol, 5 × 10-8mol, 9 × 10-9 mol, and 3.2× 10-9 mol.
in the results shown in Figure 4.5, fluorescence intensity was found to steadily
increase with the addition of ARS. Then, with the introduction of Neu5Ac, some bound
ARS was replaced by carbohydrate and fluorescence was quenched to almost 50% of the
maximum, after which it plateaued. These results indicate the efficacy of synthetic
bisboronic acid lipid 4.6b for binding both ARS and Neu5Ac. Also, the competitive three68

component fluorescence binding assay was proven to be effective for measurement of
binding interactions.
This competitive three-component fluorescence assay was applied to examine the
binding affinity of all bisboronic acid lipids 4.6a-e toward Neu5Ac. Instead of titrating ARS
solution and measuring the fluorescence intensity upon each addition, 10μL of 2mM ARS
solution was added at once to 5mM solutions of PC liposomes containing 10% bisboronic
acid lipids 4.6a-e to reach maximum fluorescence intensity. Then, 1μL of Neu5Ac was
titrated into the system as previously described, with the results shown in Figure 4.6.
Here, all of the bisboronic acid liposomes exhibited a decrease in fluorescence intensity
when Neu5Ac was introduced and plateaued before the endpoint. Among them, o-xylene
bisboronic acid lipid 4.6a yielded the most significant fluorescence drop (~70%), followed
closely by m-xylene bisboronic acid lipid 4.6b, while 2,6-naphthyl bisboronic acid lipid
4.6d exhibit the lowest fluorescence decrease (~20%). In all of these data, we have
deducted the change in fluorescence caused by dilution, which is measured by titration
with buffer instead of Neu5Ac. Another set of negative control involved the use of 100%
PC liposomes, for which data were not plotted since no fluorescence increase occurred
after the addition of ARS, confirming that the bisboronic acids were responsible for the
binding of ARS. These experiments indicated that bisboronic acid lipids with different
spacers possess variable affinities towards Neu5Ac and that the most effective were oxylene bisboronic acid lipid 4.6a and m-xylene bisboronic acid lipid 4.6b.
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4.4 Fluorescence-based dye leakage assay
4.4.1 Porcine mucin triggered bisboronic acid liposomes release of sulforhodamine b
Following the sialic acid binding study, we next moved to test triggered release
properties using bisboronic acid lipids 4.6a-e incorporated into phospholipid vesicles
through titration with porcine mucin, shown in Figure 4.7 (hydrophilic dye) and Figure
4.10 (hydrophobic dye). As discussed in section 2.1.2 mucin is a glycoprotein that is
primarily composed of carbohydrate units (60 - 80% of the molecular weight).[164, 165]
The target carbohydrate of this project, sialic acid, is the terminal glycan on Oglycosylated sugar branches and makes up around 1.2% of the total composition of mucin.
We first studied the capabilities of bisboronic acid liposomes for releasing
hydrophilic compounds. To do so, liposomes containing 10% bisboronic acids 4.6a-e were
loaded with the fluorescent dye Sulforodamine B. Figure 4.8 shows the efflux curve for a
typical trigger release measurement from PC-based vesicles, where background
fluorescence was measured without the addition of mucin. Subsequent measurements
were taken at 80 μg intervals of mucin addition for 20 additions. At the end of the
titration, 1μL of 1%(v/v) Triton X-100 (TX100) was added. As one of the most widely used
nonionic surfactants for permeabilization of membrane bilayers, TX100 leads to 100%
leakage of the vesicle contents. Specifically, liposomes containing m-xylene bisboronic
acid lipid 4.6b spacer showed the greatest amount of release of Sulforhodamine B (~ 50%
signal increase). On the other hand, liposomes containing 2,6-naphthyl bisboronic acid
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lipid 4.6d showed the least amount of release of Sulforhodamine B (less than 5% signal
increase). Background release (~10% signal increase) of liposomes containing 0%
bisboronic acid lipids was observed. The reason why more dye leakage was found in
liposomes containing only PC than liposomes containing 2,6-napthyl or 4,4-biphenyl
bisboronic acid 4.6d/e was unclear.
Results obtained for DLS measurements indicated significant liposome disruption
upon mucin treatment. As illustrated in Figure 4.9, liposomes containing either 0% or 10%
of any of the bisboronic acid lipids showed uniform liposome formation with Z average
values of approximately 200 nm before titration with mucin, supporting the formation of
stable liposomes of the expected sizes using these compounds. After addition of mucin,
PC liposomes lacking any bisboronic acid lipids showed no size change, while nearly all
the liposomes containing 10% bisboronic acid lipids yielded a major size increase. In line
with previous results, m-xylene bisboronic acid lipid 4.6b yielded the most significant size
change (~1500nm size increase), which matched the data from fluorescence efflux
studies. Increases in particle sizes detected by DLS are often an indication of morphology
changes of self-assembled lipids.
There are many possible explanations for this phenomenon. First, boronic acid
lipids located on different liposomes can be brought into close proximity when interacting
with mucin, which, along with the destabilization of membrane bilayers, can lead to
liposomal fusion and aggregation. Second, conformational changes that result from the
formation of boronate esters as a result of binding between bisboronic acid lipids and diol
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units on mucin could also drive changes in lipid self-assembly. The sp3 hybridized C-N
bond located within the bisboronic acid lipid structure can also rotate to enhance the
interaction with mucin. This can cause turbulence of the sample caused by destabilization
of the liposome bilayer structure.

4.4.1 Porcine mucin-triggered release of Nile red from bisboronic acid liposomes
To mimic non-polar drugs, the hydrophobic fluorophore Nile Red was also studied.
As can be seen in Figure 4.8, titration with mucin also led to varied levels of fluorescence
decreases depending upon the particular bisboronic acid lipid that was incorporated into
liposomes at 10% composition. Specifically, liposomes containing bisboronic acid with the
m-xylene spacer (4.6b) showed maximum release of Nile red (~ 25% signal decrease). On
the other hand, liposomes containing bisboronic acid lipid with the 4,4-biphenyl spacer
(4.6e) showed minimal release of Nile red (~12% signal decrease). Overall, the results
matched up well with the binding abilities observed in the sialic acid dye displacement
assays and the Sulforhodamine B release experiments. Minimal background release (~5%)
from liposomes containing 0% bisboronic acid lipids was observed. These data provide
evidence that the bisboronic acid units presented on the liposomes can trigger Nile red
to release to a significantly different extent, indicating their varied binding affinity
towards the glycoprotein mucin.
We have also observed that the extent of release from liposomes can vary
depending on the concentration of liposomes used for studies. Thus, we also performed
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experiments in which the total concentrations of liposomes were decreased to 500 μM
(Figure 4.9). In these experiments, while the trends for release were similar among the
different bisboronic acids, the overall extent of release was found to be greater for all
samples, including controls. Liposomes containing bisboronic acid lipid 4.6b with a mxylene spacer showed maximum release of Nile red (~ 50% signal decrease). On the other
hand, liposomes containing bisboronic acid lipid 4.6e with the 4,4-biphenyl spacer
showed minimal release of Nile red (~27% signal decrease). Compared to the previous
study of 5mM liposomes, background release was more significant in this case since an
~20% decrease in fluorescence intensity was observedusing PC liposomes lacking
bisboronic acid lipids.
The reason why more significant release was observed in all samples, including
controls, is perhaps more complex than can be succinctly explained in this dissertation.
This could be explained by the fundamental increase of micellar size and the
polydispersity upon buffer dilution of phospholipids bilayer solutions.[277] Furthermore,
the author believes this may have something to do with changes in osmotic pressure
when the liposomes were diluted to 500μM. The morphology of lipid bilayers can vary in
response to environmental changes and osmotic pressure is one of the most-studied
factors involved in bilayer homeostasis.[278, 279] The osmotic pressure on each
individual liposomal vesicle is different when the same amount of mucin glycoprotein is
added to a 5mM liposome stock as opposed to a 500μM liposome stock. Subjecting dilute
liposomes to high osmotic pressure could disrupt the integrity of their spherical bilayer
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structures and result in more content release.
Results from DLS experiments also indicated changes in liposome particle sizes
upon mucin treatment, as shown in Figure 4.10. The average size of mucin is around
800nm. In these studies, all liposomes consisting of a particular bisboronic acid lipid of
type 4.6a-e ranging from 0-10% mixed with PC yielded the expected sizes following
extrusion through a 200nm filter during liposome preparation. This indicates stable
liposomes were correctly formed when bisboronic acid lipids were mixed with PC at these
percentages. Upon treatment with mucin, liposomes containing 0% bisboronic acid lipids
exhibited minimal change in size and polydispersity index (the latter data not shown),
which matches the lack of change in Nile red fluorescence from release studies. Solutions
of 5mM liposomes containing 10% bisboronic acid lipids showed slight changes (~10 to
60nm) in sizes upon mucin addition, while 500µM samples of bisboronic acid liposomes
had more significant increase in sizes (~100 to 150nm) and a profound jump in
polydispersity index (~0.6). However, size changes were not as profound as the studies of
liposomes containing monoboronic acid lipid 3.5 triggered by heparin titration in chapter
two.
Several factors may contribute to this phenomenon. First, since there are two
boronic acid headgroups presented on one bisboronic acid lipid and they are linked with
a rigid aromatic space in a fixed geometry, molecular orientation is limited when lipids
interact with polyols in carbohydrates. Second, bisboronic acid lipids generally yielded
diminished fluorescence intensity decreases compared to mono-boronic acid lipids, which
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suggests that less reorganization of lipids is occurring when binding to mucin. Despite the
diminished changes observed during DLS results, the efflux curves obtained from
fluorescence titration provided evidence of carbohydrate binding when sufficient boronic
acids are presented on the liposome surface that leads to vesicle leakage and dye release.
A more precise and intuitive way to understand the changes of liposome size and
structure upon titration with mucin is STEM, for which experiments will be done in the
future.

4.5 Cellular delivery studies
With successful results from triggered-release studies, we next set out to assess
cellular labeling and delivery of bisboronic acid liposomes to melanoma A375 cells, as
depicted in Figure 4.14. These experiments were done in collaboration with the Barrera
lab in the Department of Biochemistry and Cellular and Molecular Biology at UTK. In these
experiments, we incubated liposomes containing bisboronic acid lipids 4.6b with cells to
allow the interaction between cell surface glycans and boronic acid moieties. The close
proximity resulting from this interaction along with the self-assembled characteristics of
the liposomes, including fluorescent Rd-PE, is expected to enhance entry into cells leading
to increased fluorescence in microscopy experiments. Since bisboronic acid lipids
containing the m-xylene spacer (4.6b) showed relatively high binding affinity to sialic acids
and the most significant liposomal dye release, this compound was selected for cell
delivery studies. Cells were incubated with 1mM of LUVs containing 0.08% Rd-PE, in the
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presenceof liposomes containing 0%, 2%, 5% 10% of 4.6b, and otherwise composed of
PC, for 2 hours at 37°C. After proper washing, cells were fixed and mounted on glass slides
for confocal laser scanning microscope.
Representative images of at least 3 experiments are shown in Figure 4.15. In these
images, the orange signal arises from the Rd-PE channel, while the blue shows DAPI
staining of nuclei to show the presence of live cells. Cells treated with liposomes
containing 4.6b (Figure 4.15B-D) resulted in significant fluorescence compared to those
of control studies lacking 4.6b (Figure 4.15A). More specifically, a dose-dependent
response was observed in which liposomes containing 10% of 4.6b had the most intense
fluorescence signal while liposomes containing 2% of 4.6b had the least fluorescence
signal. Regarding cytotoxicity, neither liposomes containing 2%, 5% or 10% of 4.6b
showed any cytotoxicity or caused any cell morphology changes, as judged from the
images. These results provide strong evidence that our synthetic bisboronic acid lipid 4.6b
can enhance cellular delivery of liposomesat a low dose while avoiding cell damage.

4.6 Summary and future outlook

In conclusion, we have designed, synthesized and analyzed novel bisboronic acid
lipids 4.6a-e, which showed variable binding abilities towards sialic acids, and were
effective for triggering release of both hydrophobic and hydrophilic compounds and
enhancing delivery to cancer cells. Despite the unnatural structures of synthetic
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bisboronic acid lipids, we validated their ability to form stable and uniformly sized
liposomes through DLS upon incorporation into PC liposomes. We observed wide-ranging
extents of content release through changes in fluorescence intensity when liposomes
included bisboronic acid lipids 4.6a-e, which supports their varied binding affinities
towards sialic acids. We then selected compound 4.6b and studied its potential as a drug
delivery agent to cancer cells, since 4.6b showed the strongest interactions with Neu5Ac
and sialic acids-rich glycoprotein mucin. To do so, melanoma cells were treated with
fluorescent liposomes containing 4.6b and strong labeling was observed through confocal
microscopy in a short period of time with minimal cytotoxicity.
There are additional experiments that can be done to further explore the potential
of bisboronic acid lipids 4.6a-e. We have investigated the binding affinity of bisboronic
acid liposomes towards Neu5Ac, and shown that structural alterations lead to variable
binding properties. To build on this work, we can screen for the selectivity of bisboronic
acid liposomes towards different carbohydrates, and particularly those that are
additionally present in mucin-1 such as glucose, galactose, and fucose. It would be
interesting to see if the compounds that yielded the highest binding affinity towards
Neu5Ac would also exhibit enhanced selectivity for this sugar. Apart from the selectivity
arising from the spatial arrangement between the two boronic acid units within the
bisboronic acid, potential selectivity towards sialic acid could also benefit from the
intrinsic favored diol location on Neu5Ac. The seminal work reported by the Wang lab has
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shown that the Keq of the phenylboronic acid sialic acid interaction is fives time higher
than that with glucose.[5]
More sophisticated cellular delivery studies can also be done to obtain a greater
understanding of how bisboronic acid liposomes behave in biological environments. To
evaluate the impact of sialic acids located on the cell surface, we could remove them first
and compare the difference in cell entry using bisboronic acid liposomes. One way to do
that is to use commercially available sialidase enzymes, which can cleave terminal sialic
acid residues that are linked to monosaccharides, oligosaccharides, glycolipids, or
glycoproteins via glycosidic bonds. Several research groups have reported that cell entry
was minimal using boronic acid material after cells were treated with sialidase.[64, 270,
280-282]
In conclusion, we have designed bisboronic acid lipids that showing varied binding
affinity towards sialic acids based on the specific spatial arrangement of the boronic acid
moieties. Liposomes containing these compounds have also been shown to effective for
triggered release of encapsulated contents in the presence of mucin-1 as well as
enhanced cell delivery. Further work is planned to probe the carbohydrate-binding
selectivity of these structures. This works presents a promising platform for selective
cancer cell drug delivery.
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4.7 Materials and method
General experimental. Reagents and solvents were generally purchased from Acros,
Aldrich or Fisher Scientific and used as received. Mucin from porcine stomach was
purchased from Sigma-Aldrich, Inc. L-α-Phosphatidylcholine (mixed isomers from egg) and
L-α-phosphatidylethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt)
were purchased from Avanti Polar Lipids, Inc. Dry solvents were obtained from a Pure Solv
solvent delivery system purchased from Innovative Technology, Inc. Column
chromatography was performed using 230–400 mesh silica gel purchased from Sorbent
Technologies. NMR spectra were obtained using Varian Mercury 300 or 500 MHz
spectrometers. Mass spectra were obtained with JEOL DART-AccuTOF or Applied
Biosystems/ QStar Elite HPLC—QTOF spectrometers. Fluorescence titration experiments
were performed using a Cary Eclipse Fluorescence Spectrophotometer from Agilent
Technologies. Water for liposome preparation and triggered -release studies was purified
using a Milli-Q filtration system. Data were plotted and curve-fitted using SigmaPlot 13.
Dynamic Light scattering (DLS) measurements were performed to study the size and
stability of liposomes using a Malvern Zetasizer Nano ZS instrument equipped with a HeNe 633 nm laser and a temperature controller at a scattering angle of 173°. All plots
represent the average of at least 3 experiments with error bars denoting +/- the standard
error for each set of measurements.
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Synthesis
Bisboronic acids with aromatic spacers 4.6a-e
Compound 3.5 (2-((dodecylamino)methyl)phenyl)boronic acid was prepared following
the protocol provided by Best and coworkers, and in chapter 3 of this dissertation.[71]
Compound 3.5 (100mg, 0.3 mmol) was dissolved in 10 mL dry dimethylformamide (DMF),
together with the appropriate dibromide corresponding to each spacer (0.16 mM, 0.53
equiv), potassium carbonate (65mg, 0.47mmol) and potassium iodide (2 mg). The
reaction mixture was heated to reflux at 90°C for 12 hr. The insoluble materials were then
filtered off, and the filtrate was washed with 3 x 100 mL water, and then with 100 mL 1M
HCl, 100 mL saturated NaHCO3 and 100 mL brine. The solvent was evaporated in vacuo
and the residue was purified on a silica gel column, eluting with hexane/ EtOAc 9:1 to give
the products. The retention factor (Rf) was ~ 0.8 on TLC plate using 25% hexane/ EtOAc
eluant mixture.

((((1,2-phenylenebis(methylene))bis(dodecylazanediyl))bis(methylene))bis(2,1phenylene))diboronic acid 4.6a
Product was obtained as white powdery solid (106mg, 0.144mmol, 96%yield). 1H NMR
(500 MHz, CDCl3) δ 7.39-7.36 (m, 3H), 7.33 – 7.28 (m, 6H), 7.25-7.20 (m, 2H), 3.55 (s,
4H), 3.54 (s, 4H), 2.40 (t, J = 7.3 Hz, 4H), 1.58 – 1.45 (m, 4H) ,1.33-1.24 (m, 36H), 0.90 (t, J
= 7.3 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 140.16, 138.38, 128.75, 128.52, 128.05,
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126.61, 58.27, 58.04, 53.41, 31.94, 29.69, 29.66, 29.53, 29.37, 27.28, 27.00, 22.71,
14.14.

((((1,3-phenylenebis(methylene))bis(dodecylazanediyl))bis(methylene))bis(2,1phenylene))diboronic acid 4.6b
Product was obtained as white powdery solid (108mg, 0.147mmol, 98%yield). 1H NMR
(500 MHz, CDCl3) δ 7.43-7.37 (m, 4H), 7.34-7.29 (m, 4H), 7.27-7.22 (m, 4H), 3.58 (s, 8H),
2.44 (t, J = 7.3 Hz, 4H), 1.58 – 1.45 (m, 4H), 1.37-1.17 (m, 36H), 0.93 (t, J = 7.3 Hz, 6H).
13

C NMR (126 MHz, CDCl3) δ 140.18, 139.81, 129.27, 128.76, 128.08, 127.84, 127.23,

126.63, 77.28, 77.03, 76.78, 58.33, 53.45, 31.97, 29.73, 29.71, 29.59, 29.41, 27.34,
27.08, 22.74, 14.16.

((((1,4-phenylenebis(methylene))bis(dodecylazanediyl))bis(methylene))bis(2,1phenylene))diboronic acid 4.6c
Product was obtained as white powdery solid (105mg, 0.142mmol, 95%yield). 1H NMR
(500 MHz, CDCl3) δ 7.39-7.25 (m, 4H), 7.32-7.28 (m, 6H), 7.25-7.20 (m, 2H), 3.55 (s, 4H),
3.54 (s, 4H), 2.40 (t, J = 7.2 Hz, 4H), 1.51 (p, J = 6.8 Hz, 4H), 1.30-1.23 (m, 36H), 0.90 (s,
6H). 13C NMR (126 MHz, CDCl3) δ 140.16, 138.38, 128.75, 128.52, 128.05, 126.60, 77.26,
77.00, 76.75, 58.27, 58.04, 53.41, 31.94, 29.69, 29.66, 29.53, 29.37, 27.28, 27.00, 22.71,
14.14.
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((((naphthalene-2,6-diylbis(methylene))bis(dodecylazanediyl))bis(methylene))bis(2,1phenylene))diboronic acid 4.6d
Product was obtained as yellow oil (39mg, 0.05mmol, 33%yield). 1H NMR (500 MHz,
Chloroform-d) δ 7.68-7.64 (M, 4H), 7.45-7.42 (m, 2H), 7.31-7.29 (m, 4H), 7.25-7.20 (m,
2H), 7.16-7.11 (m, 2H), 3.60 (s, 4H), 3.51 (s, 4H), 2.36 (s, 4H), 1.49-1.42 (m, 4H), 1.201.12 (m, 36H), 0.80 (t, J = 7.2 Hz, 6H). 13C NMR (126 MHz, cdcl3) δ 140.05, 137.21,
132.58, 128.79, 128.10, 127.48, 127.25, 126.97, 126.67, 77.27, 77.01, 76.76, 58.48,
58.28, 53.45, 31.94, 29.68, 29.66, 29.64, 29.54, 29.37, 27.30, 27.00, 22.71.

(((([1,1'-biphenyl]-4,4'diylbis(methylene))bis(dodecylazanediyl))bis(methylene))bis(2,1-phenylene))diboronic
acid 4.6e
Product was obtained as yellow oil (68mg, 0.084mmol, 56%yield). 1H NMR (500 MHz,
Chloroform-d) δ 7.57-7.51 (m, 4H), 7.46-7.39 (m, 6H), 7.34-7.31 (m, 4H), 7.25-7.23 (m,
2H), 3.60 (d, J = 3.1 Hz, 8H), 2.45 (t, J = 7.1 Hz, 4H), 1.55 (p, J = 7.6, 7.1 Hz, 5H), 1.31-1.25
(m, 36H), 0.90 (t, J = 6.7 Hz, 6H). 13C NMR (126 MHz, cdcl3) δ 140.08, 139.50, 138.99,
129.24, 129.11, 128.76, 128.11, 127.42, 126.69, 77.27, 77.02, 76.76, 58.31, 57.96, 53.47,
31.95, 29.70, 29.67, 29.55, 29.37, 27.29, 27.03, 22.71, 14.15.
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Competition binding assay of bisboronic acid liposomes through displacement of ARS
with Neu5Ac
Liposome preparation was initiated by weighing out samples of PC, bisboronic acid lipid
4.6a-e or compound 3.5, and Nile red in separate vials to make 32 mM PC, 5 mM BA lipids
stock solutions in ethanol-free chloroform. Phosphate-buffered saline (PBS, 10 mM, pH
8.0) was chosen as the buffer solution. Solutions of 2mM ARS and 50 mg/L Neu5Ac were
also prepared in PBS buffer. After brief vortexing, the appropriate volumes of the stock
solution of each lipid component and Nile red were pipetted into a clean vial per
calculations on a 5 mM, 240 µL total lipid scale, to obtain the desired molar percentage
of each component. As an example, for liposomes composed of 10% 4.6a and 90% PC,
33.8 µL PC stock (83.2 µg), 24 µL 4.6a stock (3.8 µg) were combined. After 30 seconds of
vortexing, the chloroform solvent was dried with a nitrogen stream, and the lipids were
subsequently dried for at least 3 h under vacuum. Then, the lipids were hydrated with
240 µL of PBS buffer, incubated on a 60°C water bath for 3 sets of 20 min, with vortexing
after each set. Liposomes then underwent freeze-thaw cycles between a -80°C dry iceacetone bath and a 60°C water bath for 10 cycles. Vortexing at low speed was performed
during each freeze-thaw cycle. Next, liposomes were extruded through a 200 nm
membrane filter for 21 passes using a LiposoFast extruder (Avestin, Inc.), and then added
to a fresh vial. DLS scans were performed to confirm the formation of stable liposomes.
For fluorescence-based release studies, 100 uL samples of liposome vesicles and 10 µL
ARS solution were added into a sub-micro cuvette cell (Starna Cells, Inc). After an initial
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fluorescence scan (excitation wavelength of 425 nm, emission wavelength scanned from
500 nm to 700 nm), 1 µL of Neu5Ac solution was added in the cuvette before each
fluorescence scan, which was performed 19 times. Data presented in plots indicate
emission values at 593 nm. To account for the dilution caused by the addition of Neu5Ac
solution, blank samples were run by diluting liposomes with the same volumes of buffer
solution, which were subtracted from the study samples as follows. From the observed
fluorescence during the measurement period, a normalized release function that
describes the efflux over the period of the experiment was determined according to the
equation below to exclude buffer dilution, where F(tx) and F(bx) are the measured
fluorescence at titration times x with Neu5Ac and buffer accordingly, and F(t0) and
F(b0) are initial fluorescence for the 2 different sets:
1(23) 4 1(53)

% release = 1(26) 4 1(56) * 100

Nile red Release studies upon titration of bisboronic acid liposomes with mucin
Liposome preparation was initiated by weighing out samples of PC, a specific boronic acid
lipid of type 4.6a-e or 3.5, and Nile red in separate vials to make 32 mM PC, 5 mM BA
lipids and 5 mM Nile red stock solutions in ethanol-free chloroform. Phosphate-buffered
saline (PBS, 2 mM, pH 8.0) was chosen as the buffer solution. Mucin from porcine stomach
(80 mg, bound sialic acid 0.5%-1.5%) was dissolved in 1 mL PBS buffer to make an 80
mg/mL mucin stock. After brief vortexing, the appropriate volumes of the stock solution
of each lipid component and Nile red were pipetted into a clean vial per calculations on a
84

5 mM, 240 µL total lipid scale, to obtain the desired molar percentage of each component.
As an example, for liposomes composed of 10% 4.6a, 85% PC, and 5% Nile red, 31.9 µL PC
stock (78.6 µg), 24 µL 4.6a stock (3.8 µg), and 12 µL Nile red stock (1.91 µg) were
combined. After 30 seconds of vortexing, the chloroform solvent was dried with a
nitrogen stream, and the lipids were subsequently dried for at least 3 h under vacuum.
Then, the lipids were hydrated with 240 µL of PBS buffer, incubated on a 60°C water bath
for 3 sets of 20 min, with vortexing after each set. Liposomes then underwent freezethaw cycles between a -80°C dry ice-acetone bath and a 60°C water bath for 10 cycles.
Vortexing at low speed was performed during each freeze-thaw cycle. Next, liposomes
were extruded through a 200 nm membrane filter for 21 passes using a LiposoFast
extruder (Avestin, Inc.), and then added to a fresh vial. DLS scans were performed to
confirm the formation of stable liposomes. For fluorescence-based release studies, 100
uL samples of liposome vesicles were added into a sub-micro cuvette cell (Starna Cells,
Inc). After an initial fluorescence scan (excitation wavelength of 553 nm, emission
wavelength scanned from 560 nm to 580 nm), 0.5 µL of mucin stock (0.52 U) was added
into the cuvette before each fluorescence scan, which was performed 20 times. Data
presented in plots indicate emission values at 621 nm. To account for the dilution caused
by the addition of heparin solution, blank samples were run by diluting liposomes with
the same volumes of water, which were subtracted from the study samples as follows.
From the observed fluorescence during the measurement period, a normalized release
function that describes the efflux over the period of the experiment was determined
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according to the equation below to exclude buffer dilution, where F(tx) and F(bx) are
the measured fluorescence at titration times x with mucin and buffer accordingly, and
F(t0) and F(b0) are initial fluorescence values for the 2 different sets:
1(23) 4 1(53)

% release = 1(26) 4 1(56) * 100

Sulforhodamine B liposome release studies from bisboronic acid liposomes upon
mucin titration
Stock solutions were initiated by weighing out samples of PC and bisboronic acid lipid
4.6a-e in separate vials to generate separate 32 mM PC and 5 mM 4.6a-e or 3.5 solutions
in ethanol-free chloroform. Phosphate-buffered saline (2 mM, pH 8.0) was chosen as the
buffer solution. Mucin from porcine stomach (80 mg, bound sialic acid 0.5%-1.5%) was
dissolved in 1mL PBS buffer to make 80 mg/mL mucin stock. Sulforhodamine B sodium
salt (116.1 mg) was dissolved in 10 mL PBS buffer to make a 20 mM stock solution. After
brief vortexing, proper volumes of each lipid stock solution were pipetted into a clean vial
per calculations on a 10 mM, 240 µL total lipid scale to obtain the desired molar
percentage of each component. After 30 seconds of vortexing, the chloroform solvent
was dried with a nitrogen stream, and the lipids were subsequently dried for at least 3 h
under vacuum. Next, the lipids were hydrated with 240 µL of the previously described
Sulforhodamine B stock solution and incubated on a water bath at 60°C for 3 sets of 20
min, with vortexing after each set. Liposomes then underwent freeze-thaw cycling
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between a -80°C dry ice-acetone bath and a 60°C water bath for 10 cycles. Vortexing at
low speed was performed during each freeze-thaw cycle. After that, liposomes were
extruded through a 200 nm membrane filter for 21 passes using a LiposoFast extruder
(Avestin, Inc.) and then added to a fresh vial. Next, liposomes were separated from
unencapsulated dye using a Sephadex G-50 size exclusion column (SEC). Liposomes came
out in the first or second fraction and were detected by the change in fluorescence upon
treatment of an aliquot with triton X-100. DLS scans were performed to confirm the
formation of stable liposomes. For fluorescence-based release studies, 100 µL liposome
samples were added into a sub-microcuvette cell (Starna Cells, Inc). After an initial
fluorescence scan (excitation wavelength at 553 nm, emission wavelength scanned from
560 nm to 660 nm), 0.5 µL mucin stock was added for each fluorescence measurement
with a time interval of 10 mins before quenching by adding 1 µL 1% (v/v) Triton-X 100 in
PBS to convert liposomes into mixed micelles and trigger rhodamine release. Data
presented in plots indicate emission at 606 nm. To account for the dilution caused by the
addition of mucin solution, blank samples were run by diluting liposomes with the same
volumes of water, which were subtracted from the study samples as follows. From the
observed fluorescence during the measurement period, a normalized release function
that describes the efflux over the period of the experiment was determined according to
the equation below to exclude buffer dilution where F(t), F(x) , F(0) are the fluorescence
intensity measured after adding Triton X-100, x addition time of mucin stock and initial
fluorescence intensity, respectively.:
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1(2)– 1(3)

% release = 81 − 1(2)– 1(6)< ∗ 100%

STEM Imaging Studies
Liposome solutions (5mM) containing either 0% or 10% of bisboronic acid lipid 4.6b, and
the remaining portion consisting of PC (100% or 90%, respectively) were prepared using
the standard methods described above. One portion of liposomes (100 µL) was mixed
with 10 µL (800 µg) porcine mucin, and was then incubated at rt for 30 min, while another
aliquot was mixed with 10 µL PBS buffer solution and also incubated at rt for the same
amount of time. After that, both portions were diluted to 400 µM solutions with PBS
buffer to reach ideal concentrations for scanning transmission electron microscopy
(STEM) studies. A drop (5−10 μL) from each solution was immobilized onto separate
carbon films supported by 200 mesh copper grids. After 1 minute the grid with sample
was washed with distilled water then stained with 1% uranyl acetate for 1 minute then
dried. Images were collected using a Zeiss Auriga operating in scanning transmission
mode and with a beam energy of 30 KeV.
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Cell culture and fluorescence microscopy studies of cell delivery using bisboronic acid
4.6b
Melanoma A375 cells, obtained from ATCC® (Manassas, VA), were cultured in a humidified
incubator under 5% CO2 in DMEM medium supplemented with 10% of Fetal Bovine
Serum, 50 U/mL penicillin, and 50 µg/ml streptomycin (Invitrogen). Two days prior to the
experiment, A375 cells were plated at a seeding density of 1 x 104 cells per well on a glass
bottom

96

well

plate.

Liposomes

containing

0.08%

rhodamine

L-α-

phosphatidylethanolamine (Rd-PE) as well as 0%, 2%, 5% or 10% of bisboronic acid lipid
4.6b, with the rest of the liposome consisting of PC, were incubated with cells at a
concentration of 1 mM for 2h at 37°C. Liposome preparation was conducted under
standard conditions, as described above, using 10mM PBS pH=7.4 as the buffer. After
incubation, cells were washed four times with PBS containing 1mM MgCl2 and 100mM
CaCl2 (PBS++), fixed for 30 min in 4% paraformaldehyde and the nucleus was stained with
DAPI (Invitrogen). Images were acquired on Cytation 5 plate reader (Biotek) with a 20x
lenses. Contrast and brightness settings were chosen so that all pixels were in the linear
range.
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Figure 1.1. Name and structure of oxygen-containing organoboron compounds.
The nomenclature of organoboron compounds is based on the substituents bonded to
boron atom.
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Figure 1.2. Ionization equilibrium of boronic acids in water.
In the first equilibrium (A), the boronic acid follows Brønsted–Lowry theory and the
conjugate base is generated through exchange of a proton. In the second equilibrium
(B), the boronic acid acts as a Lewis acid by accepting a pair of electrons from an oxygen
nucleophile to generate the conjugated base. It has been proven that boronic acids
show more Lewis acidity due to the vacant p orbital on boron.
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Table 1.1. Ionization constant (pKa) for selected boronic acids.
Data courtesy of review by Dennis Hall[1]
Boronic acid, RB(OH)2
Boric acid, B(OH)3
Methyl
Phenyl
3,5-Dichlorophenyl
3,5Bis(trifluoromethyl)phenyl
2-Methoxyphenyl
3-Methoxyphenyl
4-Methoxyphenyl
4-Carboxyphenyl
2-Nitrophenyl
4-Nitrophenyl
4-Bromophenyl
4-Fluorophenyl
2-Methylphenyl
3-Methylphenyl
4-Methylphenyl
3,5-Dimethylphenyl
3-Methoxycarbonyl-5nitrophenyl
2-Fluoro-5-nitrophenyl
3-Pyridyl
3-Benzyl-3-pyridylium
Quinolinyl

pKa
9.0
10.4
8.9
7.4
7.2

Reference
[3]
[3]
[4]
[4]
[4]

9.0
8.7
9.3
8.4
9.2
7.1
8.6
9.1
9.7
9.0
9.3
9.1
6.9

[5]
[4]
[6]
[7]
[8]
[6]
[4]
[4]
[9]
[9]
[9]
[4]
[11]

6.0
4.0, 8.2
4.2
4.0, 10

[5]
[5]
[5]
[10]
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Figure 1.3 Equilibrium for formation of boronate esters from diols at high and neutral
pH in aqueous solution.
Higher pH generally favors the formation of boronate esters from boronic acids and
diols because elevated hydroxide concentrations ensure the boronate ester is “locked”
in the more stable tetrahedral form.
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Table 1.2. Association constants (Keq) of phenylboronic acid with diols.
Data courtesy of paper reported by Wang and coworkers.[65]
Diol
Alizarin Red S.
Catechol
D-sorbitol
D-fructose
D-tagatose
D-mannitol
L-sorbose
1,4-Anhydroerythritol
D-erythronic-γ-lactone
L-arabinose
D-ribose

Keq (M-1)
1300
830
370
160
130
120
120
110
30
25
24

Diol
Sialic acid
cis-1,2-Cyclopentane diol
Glucuronic acid
D-galactose
D-xylose
D-mannose
D-glucose
Diethyl tartrate
Maltose
Lactose
Sucrose
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Keq (M-1)
21
20
16
15
14
13
4.6
3.7
2.5
1.6
0.67
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Figure 1.4. Structures of some representative boronic acid materials for carbohydrate
recognition and enrichment.
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Table 1.3. Structure and pKa of representative boronate affinity materials.
Type
Boronic acid with electronwithdrawing groups

Representative structures
O
S
O

Wulff-type boronic acid

OH
B
OH
HO OH
B

5.2[12]

N

H 2N

Improved Wulff-type
boronic acid
(Benzoboroxoles)

pKa
7.0[34]

OH
B
O

6.9[162]

HOOC

Heterocyclic boronic acid

OH
B
OH
N
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4.4[75]
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Figure 1.5 Representative structures of different types of complex lipids
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OH
OH

Figure 1.6. General Structure of phosphoglycerides courtesy of book chapter by
Strasser and Wittmann.[85]
The common structural features of phosphoglycerides include glycerol backbones,
phosphodiester headgroups and one or two acyl chain(s). The types of
phosphoglycerides depend on the alcohol groups bonded to phosphate and
hydrophobic fatty acids chains.
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Table 1.4. Nomenclature, headgroups, structures of common representative
phosphoglycerides
Name
Phosphat
idic acid
(PA)

Headgr Structure of representative lipids
oup
O
none
O
HO P O O
O

O

O

1-Oleoyl-2-palmitoyl-phosphatidic acid (POPA)
Phosphat
idylcholin
e
(PC)

choline

O
O
O P OO
O
N

O

O

1-Oleoyl-2-palmitoyl-phosphatidylcholine (POPC)
Phosphat
idylethan
olamine
(PE)

ethano
lamine

O
O
O P OO
O

H 3N

O

O

1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE)
Phosphat
idylglycer
ol
(PG)

O

glycero
l

OHO
OH

H O

O P O

O

O

O

1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol)
(POPG)
Phosphat
idylinosit
ol
(PI)

inositol

O
O
O
HO HO
O P OO
OH
HO OH
O
O

1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoinositol (POPI)
Phosphat serine
idylserine
(PS)

H 3N

O

H

O
O

O
O P OO
O

O

O

1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine (POPS)
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Figure 1.7. Types of drug delivery vesicles.
Several types of drug delivery vesicles have been intensively studied for their ability to
bind and recognize the targeted pathological area, including synthetic soluble polymers,
microcapsules, microparticles, cells, cell ghosts, liposomes, and micelles.
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Table 1.5. Packing parameters of representative lipids and their vesicle formation.
Packing parameter is calculated based on the lipid shape and structure. It can help to
determine the optimal shape of the product produced by lipid self-assembly. For
example, lyso-phosphatidylcholine (LPC) has a large headgroup to tail ratio, which leads
to the formation of micelles. On the other hand, due to the lack of methyl substituent,
the headgroup of phosphatidylethanolamine (PE) is smaller compared to tail, which
leads to the formation of an inverted cone shape hexagonal structure. Cylindrical lipids
such as phosphatidylcholine (PC) instead prefer the formation of membrane bilayers.
Packing
parameter
(ρ)
< 1/3

Lipid structure

Shape of assembly

N
O
O P O
O
HO
O
O

Micelle

LPC
1/2 - 1/3

NH3
O
O P O
O
O
O
O
O

Inverted Hexagonal
PE
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Table 1.5. Packing parameters of representative lipids and their vesicle formation.
(continued)
Packing
parameter
(ρ)
1/2 to 1

Lipid structure

Shape of assembly

N
O
O P O
O
O
O
O
O

PC

Bilayers
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Table 1.6. List of representative phospholipids and their transition temperatures.
Data courtesy of Avanti Polar Lipids, Inc. website. The transition temperature of
phospholipids, which is defined as the temperature where lipids transform from crystal
to gel phase, is proportional to length of acyl chain and is inversely proportional to
degree of saturation.
Name of phospholipid
12:0 Dilauroyl phosphatidylcholine (DLPC)
14:0 Dimyristoyl phosphatidylcholine (DMPC)
16:0 Dipalmitoyl phosphatidylcholine (DPPC)
18:0 Distearoyl phosphatidylcholine (DSPC)
18:1 Dioleoyl phosphatidylcholine (DOPC)
18:0 Distearoyl phosphatidylethanolamine (DSPE)
18:1 Dioleoyl phosphatidylethanolamine (DOPE)
18:0 Distearoyl phosphatidylserine (DSPS)
18:1 Dioleoyl phosphatidylserine (DOPS)
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Tm (°C)
-2
24
41
55
-17
74
-16
68
-11

Figure 1.8. Different types of liposomal drug delivery systems.
Scheme inspired by Hua’s work.[137] (A) conventional liposomes are composed of
cationic, anionic, or neutral phospholipids and cholesterol with lipid bilayers and
aqueous core. (B) PEGylated liposomes are decorated with polyethylene glycol (PEG) as
a hydrophilic coating to enhance steric stability. (C) Ligand-targeted liposomes are
modified with ligands, such as antibodies, peptides, and carbohydrates, for targeting
specific cell types (D) Theranostic liposomes are combinations of the three types above
with nanoparticles, targeting elements, imaging components and therapeutic
components
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Figure 1.9. Different type of liposome drug delivery method.
Liposomal drug delivery can generally be categorized into active targeting, which can
be achieved by liposomal surface decoration with target-specific ligands and/or
antibodies, and triggered-based targeting, which utilizes internal stimuli, such as pH or
enzymes, and external stimuli, such as ultrasound, heat, light, magnetic field
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Figure 2.1. Synthetic route to boronic acid-biotin conjugate 2.1.
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Figure 2.2. Data from UV/vis and fluorescence titrations of 2.1 into alizarin.
A. Spectral overlay of UV/vis shift with selected points from 0-600 µM 2.1. B. Plot of
absorbance increase. C. Spectral overlay of fluorescence increase. D. Plot of
fluorescence increase with selected points from 0-500 µM 2.1. Data are presented as
the average of at least three experiments with error bars depicting standard error.
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Compound 2.1
2.1

Figure 2.3. Illustration of boronic acid assay and glycoprotein detection.
Boronic acid-biotin conjugate 2.1 is immobilized onto streptavidin microplates creating
a multivalent sensor surface. Incubated glycoproteins can then bind to this surface
through boronic ester formation, and chemiluminescence detection of bound protein
can be performed without (HRP) or with (mucin-1) the use of an HRP-tagged antibody.
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Figure 2.4. Data from chemiluminescence detection of glycoprotein binding using
boronic acid microplate assay.
A. Detection of purified HRP protein binding. B. Detection of Muc1 from MCF-7 cancer
cell lysates. Data are presented as the average of at least three experiments with error
bars depicting standard error.
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3.2

3.3

3.4

Figure 3.1. Synthetic route for boronic acid lipid 3.1.
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3.1

3.5

Figure 3.2. Synthetic route for boronic acid lipid 3.5.
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key
Hydrophobic dye
Hydrophilic dye
Bulk phospholipid (PC)
Boronic acid lipid 3.1

Figure 3.3 . Fluorescence-based dye leakage assays driven by heparin-boronic acid lipid
interactions.
Hydrophobic (Nile red) or hydrophilic (sulforhodamine B) dyes are separately
encapsulated within boronic acid liposome membrane bilayers or aqueous interiors,
respectively. Heparin carbohydrate binding is evaluated for the release of contents
leading to fluorescence decreases (Nile red) or increases (sulforhodamine B) attributed
to membrane distortion upon carbohydrate binding.
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Figure 3.4. Boronic acid liposome Nile red release and DLS results upon heparin
incubation.
A. Decreases in Nile red fluorescence attributed to release are dependent upon the
percentage of boronic acid lipid 3.1 in PC liposomes. B. DLS results show that untreated
liposomes exhibit the expected sizes, while treatment of liposomes containing higher
percentages (10-20%) of 3.1 with heparin leads to much larger particle sizes attributed
to lipid reorganization. Error bars denote the standard errors of at least three replicates.
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Figure 3.5. Nile red release and DLS results upon heparin incubation using control
compound 3.4.
A. Decreases in Nile red fluorescence were much greater for PC liposomes containing
10% of boronic acid lipid 3.1 compared to those instead containing 10% of control
compound 3.4. B. DLS results show that liposomes containing 3.1 exhibit large increases
size upon heparin treatment while those instead containing compound 3.4 do not.
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Figure 3.6. Nile red release titration of liposomes containing 3.1 with HRP glycoprotein.
Decreases in Nile red fluorescence were greater for PC liposomes containing 10% of
boronic acid lipid 3.1 compared to those PC liposomes lacking 3.1.
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Figure 3.7. Boronic acid liposome sulforhodamine release results upon heparin titration.
Fluorescence increases upon sulforhodamine B release, plotted as a percentage of
increases caused by Triton X treatment, are shown to correlate with the percentage of
3.1 in PC liposomes. Error bars denote the standard errors of at least three replicates.
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Figure 3.8. Boronic acid liposome Nile red release and DLS results upon heparin
incubation using compound 3.5.
A. Decreases in Nile red fluorescence attributed to release are dependent upon the
percentage of boronic acid lipid 3.5 in PC liposomes. B. DLS results show that untreated
liposomes exhibit the expected sizes, while treatment of liposomes containing higher
percentages (10-20%) of 3.5 with heparin leads to much larger particle sizes. Error bars
denote the standard errors of at least three replicates.
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Figure 3.9. Boronic acid liposome sulforhodamine release upon heparin titration using
3.5.
A. Fluorescence increases upon sulforhodamine. B release are shown to correlate with
the percentage of 3.5 in PC liposomes. Error bars denote the standard errors of at least
three replicates.
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A

B

C

D

Figure 3.10. STEM Images.
Images are shown for liposomes containing 0% of 3.1 without (A) and with (B) heparin
treatment as well as those containing 10% of 3.1 without (C) and with (D) heparin
treatment. Scale bars correlate with 200 nm.
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Figure 3.11. Results from microplate studies indicating the binding of fluorescent
liposomes to immobilized heparin-biotin.
Error bars indicate standard errors for at least three replicates.

142

A

B

C

Figure 3.12. Cellular delivery studies.
A. Cartoon depicting liposome cell entry driven by binding interactions with cell
surface carbohydrates. B. Fluorescence image of cells treated with PC/Rd-PE
liposomes. C. Image upon treatment with PC/3.1(10%)/Rd-PE liposomes. Scale
bar depicts 20 µM. Fluorescence resulting from DAPI is shown in blue.
Fluorescence resulting from Rd-PE is shown in red.
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Figure 4.1. Selected structures from the family of sialic acids with a list of natural
substituents.
The majority of sialic acids are derivatives of neuraminic acid, such as Nacetylneuraminic acid (Neu5Ac) or N-acetyl-9-O-acetylneuraminic acid (Neu5,9Ac2)

144

B(OH)2
N
B(OH)2

OMe
OMe

(HO)2B

N

N

N
B(OH)2
4.1

4.2

O
B OH

O
H 2N

R

N
H

H
N
O

R = (CH2CH2O)3CH2CH2

O

NH

NH

O

O
HO B

O
N
H

R1

O

H
N

N
H

O

R2

20 capping groups

20 spacers
4.3

(HO)2B

B(OH)2

N

N

N

R
O

N
O

24 spacers
4.4

Figure 4.2. Structures of boronic acid-based sensors for selective recognition of
carbohydrates.
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Figure 4.3. Synthetic route for bisboronic acid lipids
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Table 4.1. Chemical structures of bisboronic acid lipids 4.6a-e
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Compounds
4.6a
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4.6b
4.6c
4.6d
4.6e
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Figure 4.4. Three-component fluorescent competition assay with Alizarin Red S (ARS).
Liposomes incorporated with bisboronic acid lipids 4.6a-z were treated with ARS to
reach maximum fluorescence intensity. Then, N-Acetylneuraminic acid was titrated into
the system to reach an excess amount. Due to the introduction of Neu5Ac, some of the
bound ARS was released into the environment, which led to a decrease in fluorescence
intensity. The binding affinity of Neu5Ac can then be estimated through data collected
from titration kinetics curves.

148

Figure 4.5. Fluorescence titration curve of liposomes containing bisboronic acid lipid
4.6b resulting from an ARS competition assay to probe Neu5Ac binding.
Titration with ARS led to a gradual increase in fluorescence due to boronate formation
that caused the removal of active protons from the ARS catechol moiety. Neu5Ac was
then titrated in, which eventually led to a decrease of almost 50% of the maximal signal,
after which the signal plateaued. Error bars denote the standard errors of at least three
replicates.
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Figure 4.6 Fluorescence titration curves of liposomes containing bisboronic acid lipids
4.6a-e upon treatment with ARS and then competition with Neu5Ac.
First, ARS solution was added to PC liposomes containing 4.6a-e leading to high
fluorescence intensity. Then, Neu5Ac was titrated in, resulting in a varied degree of
fluorescence decrease, in which liposomes with compound 4.6a had the most
significant decrease (~70%) and those with compound 4.6d had the least decrease
(~20%) in fluorescence intensity. Error bars denote the standard errors of at least three
replicates.
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Figure 4.7. Fluorescence-based Sulforhodamine B dye leakage assays driven by mucin –
bisboronic acid lipids interactions.
Hydrophilic Sulforhodamine B dyes were encapsulated within liposome aqueous
interiors. Liposomes were then titrated with mucin glycoprotein and evaluated for the
release of contents as judged by fluorescence increases, attributed to membrane
distortion upon carbohydrate binding.
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Figure 4.8. Bisboronic acid liposome Sulforhodamine B dye release results upon mucin
titration.
Data plotted are standardized as a percentage of the maximum fluorescence intensity
caused by Triton X treatment at the end of the experiment. Liposomes containing
different bisboronic acid lipids 4.6a-e showed varied fluorescence increases upon mucin
titration and the results were generally in agreement with Nile red release studies. Error
bars denote the standard errors of at least three replicates.
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Figure 4.9. DLS results of bisboronic acid liposomes incorporating Sulforhodamine B
upon mucin incubation.
DLS results showed that untreated liposomes exhibit the expected sizes based on
liposome preparation through extrusion, while treatment of liposomes containing 10%
bisboronic acid lipids 4.6a-e with mucin leads to larger particle sizes attributed to lipid
reorganization. Among them, liposomes containing compound 4.6b had the most
significant size increase, which matches the efflux data above. Error bars denote the
standard errors of at least three replicates.
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Figure 4.10. Fluorescence-based dye leakage assays driven by mucin – bisboronic acid
lipid interactions.
The hydrophobic dye Nile Red was encapsulated within bisboronic acid liposome
membrane bilayers. It was expected that when the bisboronic acid moieties reacted
with diols in the sialic acid-rich glycoprotein mucin, liposome membranes would be
disrupted and cause dye release. This leads to a decrease in Nile red fluorescence upon
release since this dye is insoluble in aqueous solution.
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Figure 4.11. Results for release of Nile red from 5mM solutions of bisboronic acid
liposomes upon mucin incubation.
(A) Decreases in Nile red fluorescence were again varied based on the particular
bisboronic acid lipids of type 4.6a-e that were incorporated into liposomes. (B) The most
significant decrease in Nile red fluorescence was from liposomes with m-xylene 4.6b
and the least amount of decrease was from liposomes with 4,4-biphenyl 4.6e.
Background release from liposomes containing only PC was minimal. Error bars denote
the standard errors of at least three replicates.
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Figure 4.12. Results from Nile red release from solutions of 500μM of bisboronic acid
liposomes upon mucin incubation.
Similar trends for Nile red release have been observed when liposomes were diluted to
500μM. However, the overall release of Nile red, including PC control liposomes lacking
4.6a-e, was more significant (ie ~20% background release from control PC liposomes)
compared to results from 5mM scale studies. Error bars denote the standard errors of
at least three replicates.
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Figure 4.13. DLS results showing changes of particle sizes of liposomes before and after
mucin incubation.
DLS results show that untreated liposomes exhibit the expected sizes, while treatment
of liposomes containing bisboronic acid lipids 4.6b-e with mucin led to slightly larger
particle sizes attributed to binding interactions and changes in lipid assembly. Studies
done at the 5 μM scale showed more significant size changes compared to those at 5
mM scale. Error bars denote the standard errors of at least three replicates.
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Figure 4.14. Cartoon depicting expected cellular delivery using bisboronic acid
liposomes.
Cartoon description of targeted delivery of fluorescent liposomes to cells through the
interaction between surface glycans and bisboronic acid lipid 4.6b. PC-based liposomes
with rhodamine-PE and/or compound 4.6b were feed to melanoma cells to facilitate
liposome cell delivery, which was assessed by fluorescence microscopy.
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Figure 4.15. Bisboronic acid lipids 4.6b binds to melanoma cells.
Figure A1, B1, C1, D1 (black and white) and Figure A2, B2, C2, D2 (blue for DAPI and
orange for Rd-PE) are images collected from confocal microscopy experiments that
were merged together using the software ImageJ. A375 cells were treated for 1 hour
with 1 mM of LUVs containing 0.08% rhodamine PE, PC in the absence (A1, A2) or
presence of 2% (B1, B2), 5% (C1, C2), 10% (D1, D2) bisboronic acid lipid 4.6b. Figure
depicts a representative image of 3 independent experiments.
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Appendix B Spectrum images
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Spectrum 2.1. 1H NMR of compound 2.3. tert-butyl (3-(2-(2-(3aminopropoxy)ethoxy)ethoxy)propyl)carbamate (2.3).
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Spectrum 2.2. 1H NMR of compound 2.4. (2-(19,19-dimethyl-17-oxo-6,9,12,18-tetraoxa-2,16diazaicosyl)phenyl)boronic acid (2.4).
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Spectrum 2.3. 13C NMR of compound 2.4. (2-(19,19-dimethyl-17-oxo-6,9,12,18-tetraoxa-2,16diazaicosyl)phenyl)boronic acid (2.4).
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+TOF MS: 2.100 to 2.116 min from Sample 1 (170509_Best_Zhang_positive) of 170509_Best_Zhang_positive.wiff
a=3.59063425142042680e-004, t0=7.51739659814686970e+001 (Turbo Spray)

Max. 1.6e4 counts.
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Spectrum 2.4. Mass spectra of compound 2.4. tert-butyl (3-(2-(2-(3aminopropoxy)ethoxy)ethoxy)propyl)carbamate (4.4).
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Spectrum 2.5. 1H NMR of compound 2.1. (2-(17-oxo-21-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4d]imidazol-4-yl)-6,9,12-trioxa-2,16-diazahenicosyl)phenyl)boronic acid (2.1).
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Spectrum 2.6. 13C NMR of compound 2.1. (2-(17-oxo-21-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4d]imidazol-4-yl)-6,9,12-trioxa-2,16-diazahenicosyl)phenyl)boronic acid (2.1)
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+TOF MS: 1.098 to 1.115 min from Sample 1 (20160411_Best_Zhang_02) of 20160411_Best_Zhang_02.wiff
a=3.59081171941098590e-004, t0=7.40646874774663640e+001 (Turbo Spray)

Max. 6.0e4 counts.
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Spectrum 2.7. Mass spectra of compound 2.1. (2-(17-oxo-21-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4d]imidazol-4-yl)-6,9,12-trioxa-2,16-diazahenicosyl)phenyl)boronic acid (2.1)
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Spectrum 3.1. 1H NMR NMR of compound 3.5. (2-((dodecylamino)methyl)phenyl)boronic acid (3.5)
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Spectrum 3.2. 13C NMR of compound 3.5. (2-((dodecylamino)methyl)phenyl)boronic acid (3.5)
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Spectrum 3.3. 11B NMR of compound 3.5. (2-((dodecylamino)methyl)phenyl)boronic acid (3.5)
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Spectrum 3.4. 1H NMR of compound 3.5. 2,3-bis(hexadecyloxy)propan-1-amine (3.4)
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Spectrum 3.5.

13

C NMR of compound 3.5. 2,3-bis(hexadecyloxy)propan-1-amine (3.4)

172

OH
HO B

NH
O

O

3.1

1

Spectrum 3.6. H NMR of compound 3.1. (2-(((2,3bis(hexadecyloxy)propyl)amino)methyl)phenyl)boronic acid (3.1)
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Spectrum 3.7. 13C NMR of compound 3.1. (2-(((2,3bis(hexadecyloxy)propyl)amino)methyl)phenyl)boronic acid (3.1)
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Spectrum 3.8. 11B NMR of compound 3.1. (2-(((2,3bis(hexadecyloxy)propyl)amino)methyl)phenyl)boronic acid (3.1)
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Spectrum 4.1. 1H NMR of compound 4.6a. ((((1,2phenylenebis(methylene))bis(dodecylazanediyl))bis(methylene))bis(2,1-phenylene))diboronic
acid (4.6a)
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Spectrum 4.2. 13C NMR of compound 4.6a. ((((1,2phenylenebis(methylene))bis(dodecylazanediyl))bis(methylene))bis(2,1-phenylene))diboronic
acid (4.6a)
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Spectrum 4.3. 1H NMR of compound 4.6b. ((((1,3phenylenebis(methylene))bis(dodecylazanediyl))bis(methylene))bis(2,1-phenylene))diboronic acid (4.6b)
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Spectrum 4.4. 13C NMR of compound 4.6b. ((((1,3phenylenebis(methylene))bis(dodecylazanediyl))bis(methylene))bis(2,1-phenylene))diboronic acid (4.6b)
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Spectrum 4.5. 1H NMR of compound 4.6c. ((((1,4phenylenebis(methylene))bis(dodecylazanediyl))bis(methylene))bis(2,1-phenylene))diboronic acid (4.6c)
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Spectrum 4.6. 13C NMR of compound 4.6c. ((((1,4phenylenebis(methylene))bis(dodecylazanediyl))bis(methylene))bis(2,1-phenylene))diboronic acid (4.6c)
181

HO

B
OH

HO
N

B

OH

N

4.6d

Spectrum 4.7. 1H NMR of compound 4.6d. ((((naphthalene-2,6diylbis(methylene))bis(dodecylazanediyl))bis(methylene))bis(2,1-phenylene))diboronic acid (4.6d)
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Spectrum 4.8. 13C NMR of compound 4.6d. ((((naphthalene-2,6diylbis(methylene))bis(dodecylazanediyl))bis(methylene))bis(2,1-phenylene))diboronic acid (4.6d)
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Spectrum 4.9. 1H NMR of compound 4.6e. (((([1,1'-biphenyl]-4,4'diylbis(methylene))bis(dodecylazanediyl))bis(methylene))bis(2,1-phenylene))diboronic acid (4.6e)
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Spectrum 4.10. 13C NMR of compound 4.6e. (((([1,1'-biphenyl]-4,4'diylbis(methylene))bis(dodecylazanediyl))bis(methylene))bis(2,1-phenylene))diboronic acid (4.6e)
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